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ABSTRACT OF THE DISSERTATION 
Glucosensing, Hypoglycemia, and the Brain 
By 
Candace Michelle Reno 
Doctor of Philosophy in Molecular Cell Biology 
Washington University in St. Louis, 2013 
Associate Professor Simon J. Fisher, Chairperson 
 
Glucose homeostasis can be peripherally and centrally mediated. Within the periphery, 
GLUT4 in muscle and adipose tissue is required for normal glucose homeostasis and 
disruption of GLUT4 translocation in these tissues leads to glucose intolerance and 
insulin resistance, hallmarks of Type 2 diabetes. Within the brain, specialized glucose 
sensing neurons regulate whole body glucose homeostasis. Unlike GLUT4’s role in the 
periphery, brain GLUT4 regulation of glucose tolerance is not well defined. 
Understanding how brain glucose sensing, mediated by GLUT4, regulates glucose 
tolerance and insulin sensitivity will aid in the development of treatment strategies to 
protect against the pathogenesis of diabetes. In addition, the brain regulates 
hypoglycemic counterregulation. Hypoglycemia is a major limitation to the treatment of 
diabetes. Severe hypoglycemia can lead to brain damage, cognitive dysfunction, and 
death. Understanding how to prevent the complications of severe hypoglycemia is 
critical to helping patients that are at risk. This thesis investigated 1) the role of brain 
GLUT4 in mediating peripheral insulin sensitivity, brain glucose sensing, and the 
counterregulatory response to hypoglycemia, 2) the effect of chronic insulin therapy in 
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protecting the diabetic brain against neuronal damage and cognitive dysfunction due to 
severe hypoglycemia, and 3) the mechanisms by which severe hypoglycemia leads to 
sudden death. Brain GLUT4 was shown to be critical for normal glucose homeostasis 
and the counterregulatory response to hypoglycemia. This indicates that therapeutic 
targeting strategies can aim to enhance brain GLUT4 function to improve glucose 
homeostasis in the setting of diabetes. Chronic insulin therapy in diabetic rats 
decreased the extent of brain damage due to severe hypoglycemia. This indicates that 
insulin therapy in diabetes decreases susceptibility to severe hypoglycemia-induced 
brain damage. The mechanisms of severe hypoglycemia induced sudden death are 
shown for the first time to be regulated by sympathetic mediated fatal cardiac 
arrhythmias. This thesis reveals the importance of the brain in the regulation of glucose 
homeostasis and the counterregulatory response to hypoglycemia and reveals 
paradoxical evidence that inhibition of the counterregulatory response acts to protect 
against severe hypoglycemia-induced mortality.  
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Chapter 1: Thesis Introduction 
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Diabetes 
 Diabetes is a growing epidemic with more than 25 million people in the US alone 
diagnosed. Diabetes is defined by an elevated blood glucose resulting from 
autoimmune destruction of pancreatic beta cells leading to insulin deficiency (Type 1 
diabetes) or a combination of insulin resistance and beta cell failure (Type 2 diabetes). 
Chronic hyperglycemia in diabetes can result in both macrovascular (heart disease, 
stroke) and microvascular (neuropathy, nephropathy, retinopathy) complications. A 
major contributor to glucose intolerance and insulin resistance in models of Type 2 
diabetes is impaired glucose transporter 4 (GLUT4) expression and/or translocation to 
the plasma membrane for insulin stimulated glucose uptake1,2. Insulin acts to lower 
blood glucose levels by both suppressing endogenous glucose production as well as 
increasing peripheral GLUT4-dependent glucose uptake. Impaired insulin action leads 
to inefficient glucose uptake into muscle and adipose tissue as well as altered regulation 
of hepatic glucose production resulting in hyperglycemia.  
Because of its potent effects to lower blood glucose, insulin is used in the 
treatment of diabetes to control blood glucose levels. However, insulin treatment leads 
to increased risk of iatrogenic hypoglycemia. Hypoglycemia prevalence in insulin treated 
diabetic patients is as high as 2.1 times per 24 hours3. To function properly, the brain is 
constantly dependent on circulating glucose. Thus when severe, hypoglycemia can 
result in seizures, brain damage4-6, cognitive decline4,7-9, coma, and even death10.  
These are all major concerns for insulin treated diabetic patients and their families. 
Determining the mechanisms of how hypoglycemia-induced brain damage, cognitive 
decline, and sudden death are regulated is critically important in order to find treatments 
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to protect patients who are at risk for hypoglycemia. This thesis will specifically address 
1) the role of brain glucose transporter 4 in glucose homeostasis, 2) the role of 
antecedent blood glucose control in reducing severe hypoglycemia induced brain 
damage and cognitive dysfunction, and 3) the mechanisms by which severe 
hypoglycemia can cause sudden death. 
 
Glucose homeostasis 
Regulation of glucose homeostasis is a tightly controlled process involving cross-
talk between liver, skeletal muscle, adipose tissue, and the brain to maintain blood 
glucose in a normal physiologic range. Insulin’s actions in the periphery to lower blood 
glucose levels have been studied extensively but its central actions have just begun to 
be elucidated. The brain has an important role in energy homeostasis due to its 
requirements for a constant glucose supply. Thus, studying the brain’s role in sensing 
and responding to changes in glucose will aid in development of better strategies to 
treat or prevent diabetes. 
 
Anatomy of brain glucose sensing  
Although all brain cells utilize glucose, only a few specialized neurons in the brain 
truly sense and respond to a reduced glucose supply. Rodent studies indicate that 
glucose is sensed in brain regions known to be important in metabolism and energy 
homeostasis, particularly in the hypothalamus, where glucose sensing neurons are 
located11. Most studies to date indicate that it is the hypothalamus that principally 
initiates (or at least coordinates) the counterregulatory response (CRR) to hypoglycemia 
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by stimulating hormone secretion in the pituitary gland, pancreas, and adrenal glands 
resulting in a coordinated response (Figure 1). Clinical studies confirm the importance of 
the hypothalamus as a critical glucose sensing area because blood flow to the 
hypothalamus increases significantly during hypoglycemia, even before 
counterregulatory hormones rise12. Within the hypothalamus, key regions that respond 
to changes in circulating glucose levels are the ventromedial hypothalamus (VMH) 
which contains the ventromedial nucleus (VMN) and the arcuate nucleus (ARC)13.  
Studies show that glucose infusion into the VMH in the setting of peripheral 
hypoglycemia blunts the epinephrine counterregulatory response to hypoglycemia14,15. 
These studies indicate that decreases in glucose are detected by the VMH and are 
required to fully activate the sympathoadrenal response to hypoglycemia.   
The VMH contains glucose excitatory (GE, increases in glucose increase 
neuronal activity) and glucose inhibited (GI, increases in glucose decrease neuronal 
activity) neurons16. Together, the actions of these neurons results in a coordinated 
process of trying to maintain plasma glucose levels within a normal physiological range. 
It is thought that in response to hypoglycemia, concerted activation of GI neurons and 
suppression of GE neurons, as an initiating part of a neural network, result in a 
coordinated efferent process that activates the sympathoadrenal response. This 
balance is disrupted in conditions such as diabetes17. 
 
Brain glucose uptake 
The brain contains different isoforms of glucose transporters (GLUT) responsible 
for neuronal and astrocyte glucose uptake. The ubiquitous GLUT1 and the neural 
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specific GLUT3 are the primary isoforms present in the brain that are responsible for 
glucose transport across the blood brain barrier and into the brain. Based on discrete 
regional expression, the potential contribution of other glucose transporters has been 
investigated. A role for GLUT2 in mediating CNS glucose sensing has been proposed18. 
In addition, because of its important role in peripheral glucose tolerance, the insulin-
sensitive brain GLUT4 has been hypothesized to play a role in glucose and energy 
homeostasis.  
 
Glucose transporter 4 
GLUT4 is an insulin sensitive facilitative glucose transporter primarily expressed 
in adipose tissue, skeletal muscle, and heart19 with a lower expression in the brain20. 
GLUT4 is expressed in various regions of the brain, including the hypothalamus (VMH, 
PVN, ARC), cerebellum, hippocampus, and cortex21, regions important in metabolism, 
learning, and memory. Translocation of intracellular GLUT4 to the plasma membrane in 
adipose tissue and skeletal muscle is important in maintaining glucose homeostasis. 
Altered GLUT4 translocation in adipose tissue and muscle leads to glucose intolerance 
and insulin resistance, both characteristics of Type 2 diabetes1,2. It has been 
hypothesized that brain GLUT4 works in a parallel insulin-dependent manner to that in 
the periphery. Similar to its known actions in peripheral tissues, GLUT4 translocation 
occurs in neuronal cell lines, hippocampus, and hypothalamus in response to insulin22-
24. In addition, studies have shown that GLUT4 expression in the brain is altered in 
response to insulin levels. Diabetic mice (db/db, hyperinsulinemia) have increased 
GLUT4 protein expression while streptozotocin induced diabetic rats (hypoinsulinemia) 
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have decreased GLUT4 protein expression in the cerebellum25. In addition, ob/ob mice 
(insulin resistant) have increased GLUT4 expression in the hypothalamus25. Therefore, 
regulation of GLUT4 protein expression in different regions of the brain may be 
dependent on plasma insulin levels or insulin sensitivity, indicating a potential 
pathogenic role for brain GLUT4 in the development of diabetes.   
In addition to insulin regulation of brain GLUT4 protein expression and 
translocation, co-localization of GLUT4 and insulin receptor (IR) within the brain 
indicates an important relationship in the regulation of metabolism. Within the VMH, up 
to 75% of the glucose sensing neurons co-express GLUT4 and IR16. Insulin receptors 
are also highly expressed in the paraventricular nucleus (PVN) and arcuate nucleus 
(ARC) of the hypothalamus26 suggesting an important role for brain insulin action in 
metabolism. A recent report from our laboratory has shown the importance of insulin 
action in the brain in mediating both glucose sensing and the counterregulatory 
response to hypoglycemia. Neuronal insulin receptor knockout (NIRKO) mice have 
impaired hypoglycemic counterregulation, characterized by a blunted epinephrine and 
norepinephrine response27. Consistent with insulin exerting its effect primarily in the 
hypothalamus, NIRKO mice have impaired glucose sensing in VMH GI neurons and 
impaired activation of PVN neurons in response to hypoglycemia27. In addition, insulin 
induced suppression of hepatic glucose production is impaired in NIRKO mice, 
confirming earlier reports of central insulin regulation of hepatic glucose production28. 
Together, these studies implicate hypothalamic insulin signaling as an important 
regulator of glucose sensing to control hepatic glucose production and the normal 
counterregulatory response to hypoglycemia. Interestingly, NIRKO mice have a 68% 
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reduction in hypothalamic GLUT4 protein expression indicating that insulin’s actions in 
metabolic homeostasis may be mediated in part by brain GLUT4. 
Because peripheral GLUT4 is important in the etiology of type 2 diabetes and 
brain GLUT4 is co-localized with the insulin receptor and its protein expression may be 
controlled by insulin, a brain GLUT4 KO (BG4KO) mouse was generated to study the 
importance of brain GLUT4 in glucose homeostasis and hypoglycemic 
counterregulation and is the focus of chapter 2. 
 
Hypoglycemia 
The treatment of diabetes remains suboptimal due to the barrier of iatrogenic 
hypoglycemia. Insulin treated diabetic patients experience an average of two 
symptomatic hypoglycemic episodes per week while severe hypoglycemia requiring 
assistance is experienced approximately once per year29. Since the brain is 
continuously dependent on glucose for metabolism, robust counterregulatory 
mechanisms exist to rapidly increase blood glucose levels in order to protect the brain 
from hypoglycemia induced neuronal dysfunction and injury. Both severe and even 
more moderate episodes of hypoglycemia can be harmful. Recurrent episodes of 
moderate hypoglycemia can lead to a decreased awareness of hypoglycemia and 
decreased counterregulation, a phenomenon known as hypoglycemia associated 
autonomic failure (HAAF)30. HAAF can lead to an increased risk of more severe 
episodes of hypoglycemia31. Severe hypoglycemia can alter brain structure4-6, cause 
brain damage4-6, cognitive dysfunction4,7-9 and sudden death10. The counterregulatory 
response (CRR) to hypoglycemia has an important role in preventing the fall in glucose 
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to reduce the risk of the damaging effects of severe hypoglycemia, but, paradoxically, 
this same response can be harmful, leading to increased susceptibility to the damaging 
effects of severe hypoglycemia.  
 
The counterregulatory response to hypoglycemia 
In the setting of absolute or relative hyperinsulinemia, the CRR is normally 
initiated when glucose levels fall below 80 mg/dl. The CRR to hypoglycemia normally 
includes suppression of endogenous insulin secretion and increased secretion of 
catecholamines (epinephrine, norepinephrine), glucagon, cortisol, and growth hormone, 
which together act to increase plasma glucose levels by stimulating hepatic glucose 
production and limiting glucose utilization in peripheral tissues (Figure 1).  
 
Sympathetic activation 
In response to hypoglycemia, patients with Type 1 diabetes and advanced Type 
2 diabetes are not able to suppress circulating (exogenous) insulin levels nor increase 
glucagon secretion32. Thus, in the absence of appropriate insulin and glucagon 
responses, patients with diabetes rely extensively on the sympathoadrenal system as 
their primary counterregulatory defense against hypoglycemia33. Adrenergic activation 
leads to the release of norepinephrine at nerve terminals located throughout the 
periphery. Within the adrenal gland, adrenergic stimulation leads to epinephrine 
secretion. Activation of the adrenergic system reverses falling glucose levels by 
increasing glucose production, reducing peripheral glucose utilization, and eliciting 
symptoms of hypoglycemia. 
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Catecholamines 
As systemic blood glucose levels fall, glucose levels within the brain also 
decrease. A fall in glucose levels within the VMH is associated with increased 
norepinephrine release in the VMH and the initiation of the counterregulatory response 
to hypoglycemia34,35. Adrenergic receptors within the brain, particularly the VMH, are 
important mediators that trigger the sympathoadrenal response to hypoglycemia36. 
However, recurrent episodes of hypoglycemia can lead to a blunted counterregulatory 
response to subsequent hypoglycemia as well as hypoglycemia unawareness, 
characteristics of HAAF. A recent study by Ramanathan et al.37 showed that 
intravenous infusion of adrenergic blockers (phentolamine and propranolol) on day 1 of 
hypoglycemia prevented the induction of counterregulatory failure in the subsequent 
response on day 2 of hypoglycemia. This study implicates that HAAF is induced by 
antecedent sympathoadrenal responses to hypoglycemia. Taken together, extending 
these findings to their potential pharmacologic and therapeutic implications indicates 
that paradoxically blocking the action of catecholamines within the CNS may protect 
against subsequent hypoglycemic bouts by limiting the development of HAAF, but 
unfortunately, blocking the action of catecholamines in the periphery would tend to 
increase the severity of acute hypoglycemia. Future research is needed to develop CNS 
specific adrenergic blockers that alter brain mediated counterregulatory responses 
without disrupting the peripheral sympathoadrenal response.  
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Glucagon 
In addition to an impaired sympathoadrenal response to hypoglycemia, insulin 
deficient diabetes also results in loss of the glucagon counterregulatory response to 
hypoglycemia38. The mechanisms that regulate glucagon secretion during hypoglycemia 
are unclear32. Recent work suggests multiple mechanisms of regulation of glucagon 
secretion including fall in glucose levels, intra-islet crosstalk39, and autonomic 
stimulation40.   
In response to hypoglycemia the counterregulatory glucagon response may be 
mediated, as least in part, via direct action on pancreatic cells41,42. In addition, other  
mechanisms of intra-islet control of glucagon secretion during hypoglycemia exist 
including  cell signaling41, indirect  cell to  cell signaling43,44, and cell secretory 
products45. In particular,  cell somatostatin secretion can stimulate glucagon secretion 
during hypoglycemia45. Somatostatin within the pancreas and in circulation is elevated 
in diabetes46 and may contribute to the defective glucagon response during 
hypoglycemia. A recent study showed that the glucagon response to hypoglycemia in 
diabetic rats can be restored by somatostatin receptor type 2 antagonism accomplished 
by infusion of a selective somatostatin receptor type 2 antagonist during hypoglycemia 
in streptozotocin-induced diabetic rats47. Pancreatic glucagon was elevated in diabetic 
rats suggesting that there is a glucagon secretory defect in diabetic rats during severe 
hypoglycemia rather than a glucagon synthesis defect. These studies suggest that 
elevated somatostatin in diabetes is one mechanism in which the glucagon response is 
lost during hypoglycemia. 
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Autonomic inputs of the pancreas include actions from both the parasympathetic 
and sympathetic nervous systems. Parasympathetic activation includes secretion of 
acetylcholine (AcH), which bind to receptors directly on the  and cells48. The 
sympathetic nervous system releases norepinephrine48. Norepinephrine acts on 2 
adrenergic receptors present on pancreatic  cells to stimulate glucagon secretion49. In 
addition, the sympathoadrenal system results in release of AcH in adrenal medulla cells 
to release epinephrine which acts on the pancreas to stimulate glucagon secretion50. 
The redundant mechanisms involved in the regulation of glucagon secretion makes the 
defects in diabetes more interesting in that many mechanisms have to fail in order get 
impaired glucagon secretion. Determining which factors are necessary and sufficient for 
glucagon secretion can potentially help patients at risk for recurrent hypoglycemia 
(impaired epinephrine responses) better combat hypoglycemic bouts in order to prevent 
severe hypoglycemia. 
 
Severe hypoglycemia  
Defects in the brain’s ability to sense changes in glucose levels can lead to 
impairments in the hypoglycemia induced counterregulatory response, which in a 
viscous cycle can lead to more severe episodes of hypoglycemia characterized by brain 
damage, cognitive impairment, and even death. Understanding the mechanisms that 
lead to severe hypoglycemia-induced brain damage and sudden death is important to 
help patients who are at risk for hypoglycemia. 
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Hypoglycemia and brain damage 
Acute severe hypoglycemia induces neuronal damage in the cortex and 
hippocampus51-53. Deficits in learning and memory have been shown to be a direct 
consequence of severe hypoglycemia-induced hippocampal neuronal damage51,53,54. 
However, clinical studies investigating severe hypoglycemia effects on cognition have 
been variable, with some demonstrating7,55,56 and others not demonstrating57-59 
cognitive problems. In our laboratory, a rat model of recurrent hypoglycemia revealed 
that brain damage and cognitive defects induced by severe hypoglycemia could be 
protected by exposure to recurrent moderate hypoglycemia60 demonstrating a functional 
relationship between brain damage and long-term cognitive function. In addition, it has 
been reported in our lab that diabetes per se increases the extent of severe 
hypoglycemia induced neuronal damage61, but neither the effects on long term cognitive 
function nor the effects of insulin treatment were studied. Consistent with the notion that 
insulin deficiency worsens outcomes following brain insults, insulin has been shown to 
protect cells from death in both in vitro62-66 and in vivo67,68 studies. It was hypothesized 
that restoration of near normal glucose levels with chronic insulin therapy in diabetic rats 
protects against severe hypoglycemia-induced brain damage and cognitive dysfunction 
and is the focus of chapter 3. 
 
Hypoglycemia and Mortality 
Although fortunately rare, severe hypoglycemia can be lethal. The sudden 
unexplained death of patients with Type 1 diabetes has been noted by Tattersall and 
Gill69 and others70-78 with death 10-fold higher in young people with Type 1 diabetes78. 
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The “dead in bed syndrome” identifies otherwise healthy young individuals with Type 1 
diabetes that were found dead in bed with no clear cause of death75,77,79. Recent case 
reports consistently suggest that severe hypoglycemia due to excess insulin 
administration contributed to their death70-74,76,77,80. Given the rise of the number of 
cases of the dead in bed syndrome, research is needed in order to understand the 
mechanisms by which severe hypoglycemia can be lethal. 
Central nervous system glucopenia is thought to be the major contributor to 
severe hypoglycemia-induced mortality. The brain cannot function properly without a 
continuous supply of glucose from the blood. During hypoglycemia, lack of brain 
glucose can lead to neuronal damage81 and seizures82,83 both of which may increase 
susceptibility to mortality. For instance, studies of sudden death in epileptic patients 
showed that seizures triggered an autonomic response leading to fatal cardiac 
arrhythmias84. In our model of insulin induced severe hypoglycemia, lack of brain 
glucose leads to seizures60,61; however, whether or not seizures correlate with 
increased risk of fatal cardiac arrhythmias in the setting of severe hypoglycemia is 
unknown. 
Acute onset cardiac arrhythmias are speculated to be the primary cause of 
severe hypoglycemia-induced sudden death. Clinical studies using electrocardiograms 
(ECG) have found that cardiac arrhythmias associated with QTc prolongation occur 
during moderate hypoglycemia in both healthy and diabetic patients85-90. QTc 
prolongation represents dispersion of ventricle depolarization and repolarization and 
can lead to increased risk of fatal cardiac arrhythmias91-94. However, due to the difficulty 
of studying the complications of severe hypoglycemia in a clinical setting, studies are 
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unable to confirm that fatal cardiac arrhythmias result from severe hypoglycemia in the 
human population. 
In addition to central nervous system counterregulation to hypoglycemia, 
systemic regulation of hypoglycemia can lead to cardiac arrhythmias74,85-87. It is well 
established that enhanced catecholamine levels can cause ventricular arrhythmias95,96. 
In addition, patients exposed to moderate levels of hypoglycemia (~45 mg/dl) 
experienced cardiac arrhythmias associated with QTc prolongation that could be 
rescued with potassium or beta blocker infusion88. In the setting of insulin-induced 
hypoglycemia, both the insulin induced decrease in potassium levels and the 
counterregulatory induced increase in catecholamine levels have been speculated to 
contribute to fatal cardiac arrhythmias88,97-99. This thesis tests the hypothesis that the 
prevention of hypokalemia and/or adrenergic receptor blockade protects against 
arrhythmias and cardiorespiratory arrest during severe hypoglycemia.  It also examines 
the extent to which cardiac arrhythmias are centrally mediated. Whether central or 
systemic, possible mechanisms by which fatal cardiac arrhythmias occur during severe 
hypoglycemia are increased catecholamine surge88,97, hypokalemia88,97,  seizures81, 
and/or hypoxemia that occurs with apneic episodes100. Exploration of these potential 
mediators of sudden death due to severe hypoglycemia is the focus of chapter 4. 
 
Summary 
The brain has recently been shown to be an important regulator of whole body 
glucose homeostasis, but how the brain plays a role in the pathogenesis of diabetes is 
not well defined. Brain-mediated metabolic regulation has implications for the 
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development of drug targeting strategies that can target the brain without adverse 
effects on peripheral metabolism. In addition, diabetes treatment strategies are currently 
limited due to the concern of iatrogenic hypoglycemia. Therefore, this thesis aims to 
address how brain glucose sensing controls peripheral metabolism and how the 
complications of severe hypoglycemia induced brain damage and mortality can be 
prevented.  
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Figure 1. The counterregulatory response to hypoglycemia. Hypoglycemia is first 
sensed in various brain regions including the hypothalamus (HYP) and brain stem. Low 
glucose in these brain regions stimulates the autonomic nervous system to release 
norepinephrine and acetylcholine at postganglionic nerve terminals. A principal 
counterregulatory response is the secretion of glucagon which may be stimulated by 
various mechanisms including independent α-cell glucose sensing, autonomic 
innervation, epinephrine stimulation, and a decrement of intra-islet insulin secretion.  Via 
autonomic stimulation, epinephrine is released from the adrenal medulla.  Not shown is 
the hypothalamic-pituitary-adrenal axis by which the release of adrenocorticotropic 
hormone (ACTH) from the pituitary stimulates cortisol release from the adrenal cortex. 
The net effect of the autonomic nervous system and counterregulatory hormones is to 
act at the level of the liver to increase hepatic gluconeogenesis and glycogenolysis 
while action at muscle and adipose tissue (fat) decrease peripheral glucose utilization.    
17 
 
 
 
 
 
 
 
 
 
Chapter 2. Glucose Intolerance, Insulin Resistance, and Impaired Hypoglycemic 
Counterregulation in Brain GLUT4 Knockout Mice 
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Abstract 
The role of insulin-responsive glucose transporter 4 (GLUT4) in the central nervous 
system has not been well characterized. To assess its importance, a selective knock-
out of brain GLUT4 (BG4KO) was generated by crossing Nestin-Cre mice with GLUT4-
floxed mice. BG4KO mice had a 99% reduction in brain GLUT4. Despite normal fed and 
fasting glycemia, BG4KO mice were glucose intolerant, demonstrated hepatic insulin 
resistance, and had reduced brain glucose uptake during a hyperinsulinemic clamp.  In 
response to hypoglycemia, BG4KO mice had impaired glucose sensing noted by 
impaired epinephrine and glucagon responses and impaired c-fos activation in the 
hypothalamic paraventricular nucleus. Moreover, in-vitro glucose sensing of glucose 
inhibitory neurons from the ventromedial hypothalamus was impaired in BG4KO mice.  
In summary, glucose intolerance, insulin resistance, and impaired glucose sensing in 
BG4KO mice indicate a critical role for brain GLUT4 in sensing and responding to 
changes in blood glucose.    
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Introduction 
 The facilitative glucose transporter 4 (GLUT4) is the major glucose transporter in 
skeletal muscle, heart, and adipose tissue. In response to insulin stimulation, GLUT4 is 
translocated to the plasma membrane to facilitate glucose entry into the cell101,102. 
Disruption of GLUT4 in either skeletal muscle or adipose tissue leads to impaired 
glucose tolerance and insulin resistance, two prominent features associated with the 
pathogenesis of diabetes1,2. GLUT4 is also expressed in the brain21, although the 
physiological role of GLUT4 in the brain has yet to be elucidated. The level of brain 
GLUT4 protein expression appears to be dependent on insulin levels, as the diabetic 
hyperinsulinemic db/db mouse has increased GLUT4 expression while the insulin 
deficient streptozotocin diabetic rodent has reduced brain GLUT4 levels103. 
Interestingly, neuronal insulin receptor knockout (NIRKO) mice have a 68% reduction in 
hypothalamic GLUT4 protein27. Together, this suggests a potential important role of 
insulin responsive GLUT4 in the brain.   
GLUT4 is expressed predominantly in neuronal cells in discrete regions of the 
brain, including the hippocampus, cortex, and cerebellum. Of particular interest is that 
GLUT4 is also expressed in the hypothalamus, an area important in the regulation of 
whole body glucose and energy homeostasis21. Interestingly, GLUT4 is co-expressed 
with the insulin receptor in glucose sensing neurons16. Whether dependent or 
independent of brain insulin action, GLUT4 is strategically located to play an important 
role in the neuronal glucose sensing and modulating whole body glucose homeostasis.   
 To determine the physiological role of GLUT4 in the brain, GLUT4 was 
selectively knocked-out in the brain using a Cre-Lox approach and the effects on whole 
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body glucose homeostasis were examined. Mice with brain specific GLUT4 knock-out 
(BG4KO) were found to be glucose intolerant, have reduced insulin sensitivity, impaired 
counterregulatory responses to hypoglycemia and impaired hypothalamic glucose 
sensing in glucose inhibited (GI) neurons. Thus, these studies identify a novel role for 
brain GLUT4 in regulating whole body energy homeostasis.   
 These studies are part of co-authored work with a previous graduate student, 
Erwin Puente. There was equal contribution to the writing and execution of the 
experiments. I helped write and fully revise the text for this section. I maintained the 
mouse colony. The experiments which I conducted were the hyperinsulinemic, 
euglycemic clamps and all assays associated with them including glucose turnover and 
glucose uptake in brain, adipose, and skeletal muscle. I performed all experiments for 
western blots of hypothalamic and liver pAkt and Insulin receptor. I performed the 
hyperinsulinemic, hypoglycemic clamps for the whole body GLUT4 knockout mice and 
also did the c-fos assays for that experiment. I also set up the collaboration with V 
Routh for the electrophysiology studies conducted in her lab. I helped with many of the 
other experiments described in this chapter. 
 
Methods 
Animals.  To create brain specific GLUT4 KO mice, GLUT4 floxed mice1,2,104 
were crossed with transgenic mice that expressed Cre recombinase under the neuron 
specific promoter nestin105-107. Male mice of the C57Bl6 background were used at 2-4 
month of age in all studies unless otherwise specified.  The 4 experimental groups 
were: wild-type mice (GLUT4(+/+);nestin-Cre(-/-)); mice that have both GLUT4 alleles 
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floxed (GLUT4(lox-lox);nestin-Cre(-/-)); mice expressing Cre under the nestin promoter 
(GLUT4(+/+);nestin-Cre(+/-)); and brain specific GLUT4 knockout mice (GLUT4(lox-
lox);nestin-Cre(+/-)). For whole body GLUT4 knockout studies, Zona pellucida Cre mice 
were crossed with GLUT4 lox mice and generously provided by B. Kahn. Mice were 
genotyped by PCR analysis of DNA extracted from tail tissue using previously 
established primers and PCR conditions1,2,105,106. 
Mice and male Sprague-Dawley rats were housed in a temperature and light 
controlled environment maintaining the animal’s diurnal cycle (12hrs light, 12hrs dark) 
and fed a standard rodent chow ad libitum.  All procedures were in accordance with the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health 
and were approved by the Animal Studies Committee of Washington University. 
 
Western blot analysis. Brain, skeletal muscle, heart, and white adipose tissue were 
homogenized, centrifuged, and transferred to nitrocellulose membrane (Bio-Rad, 
Hercules, CA), and were immunoblotted with antibodies against GLUT1 (1:1000, 
Chemicon, Temecula, CA), GLUT3 (1:2000, Chemicon, Temecula, CA), GLUT4 
(1:1000, Chemicon, Temecula, CA), or against the loading control β-actin (1:6000; 
Sigma, St. Louis, MO)27. Hypothalamus and liver were immunoblotted with antibodies 
against pAKT (1:500, Cell Signaling, Danvers, MA), tAKT (1:500, Cell Signaling, 
Danvers, MA) Insulin Receptor anti-CD220, 1:500 BD Biosciences, San Jose, CA 
and β-actin from 5 hour fasted mice 30 minutes (hypothalamus) or 15 minutes (liver) 
after intraperitoneal injection of human regular insulin (3U/kg body weight) or saline 
injection. Horseradish peroxidase-conjugated secondary antibody (1:8000, Cell 
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Signaling, Boston, MA) was used and antibody binding was detected by enhanced 
chemiluminescence ECL reagents (Perkin Elmer, Waltham, MA) on ISO-MAX films and 
quantified by ImageJ software analysis. 
 
Glucose and insulin tolerance tests. Glucose tolerance tests (GTT) were 
accomplished by intraperitoneal injection of glucose (2 g glucose/kg body weight) after 
an overnight fast (15-17 hr).  Tail vein blood samples (20 μl) were taken before injection 
and at 15 minute intervals during the GTT to measure plasma insulin levels.  Insulin 
tolerance tests (ITT) were performed in 5 hour fasted mice by intraperitoneal injection of 
human regular insulin (1 U insulin/kg body weight; Lilly, Indianapolis, Indiana). Tail vein 
blood glucose was measured using Ascensia Contour (Bayer HealthCare, LLC, 
Mishawaka, IN) blood glucose monitors. 
 
Glucose stimulated insulin secretion. First phase glucose stimulated insulin secretion 
in overnight (15-17 hr) fasted mice was assessed following an intraperitoneal injection 
of glucose (3 g glucose/kg body weight). Tail vein blood samples (20 μl) were taken for 
glucose and insulin determinations immediately before injection and at 2, 5, 15, and 30 
minutes after injection.   
 
Hyperinsulinemic-euglycemic clamp, glucose kinetics analysis, and brain glucose 
uptake. Hyperinsulinemic (4 mU.kg-1.min-1)-euglycemic (~110 mg/dl) clamp studies 
were performed as previously described108. Micro-renathane catheters (Braintree 
Scientific Inc., Braintree, Massachusetts, USA) were implanted in the jugular vein and 
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femoral artery of anesthetized mice (Ketamine 87 mg/kg and Xylazine 2.6 mg/kg). 
Hyperinsulinemic-euglycemic clamp studies were conducted 5–8 days after surgery in 
awake, freely mobile mice after a 5-hour fast.  Whole-body glucose flux was determined 
using a continuous infusion of [3-3H] glucose (PerkinElmer, Boston, Massachusetts, 
USA) at 0.05 μCi/min after an initial 5-μCi bolus. After a 90 minute basal period, 
samples were taken for basal plasma insulin levels and plasma [3H]-glucose 
measurements. A primed (40 mU/kg) continuous infusion (4 mU.kg-1.min-1) of human 
regular insulin (Humulin; Eli Lilly and Co.) in 0.1% BSA was co-administered with 50% 
glucose at variable rates to maintain blood glucose at approximately 110 mg/dl.   
Tissue-specific insulin-stimulated glucose uptake was measured with a bolus (5 
μCi) of 2-deoxy-D-[1-14C] glucose (2-[14C]DG; Amersham) administered 45 minutes 
before the end of the clamp. For plasma 2-[14C]DG measurements, blood samples were 
taken immediately before 2-[14C]DG administration and at 0.5, 2, 3, 5, 10, 15, 20, 30, 
and 45 min following administration. Blood samples were taken at the end of the clamp 
for plasma [3H]glucose and plasma  insulin measurements. Immediately following the 
clamp, mice were euthanized and skeletal muscle and adipose tissue were rapidly 
dissected and frozen in liquid nitrogen. Brains were harvested and quickly frozen in a 
dry ice and 2-methylbutane (Fisher, Saint Louis, MO) bath (-20o C).  Plasma [3-3H] 
glucose and 2-[14C]DG concentrations were determined by a dual-channel scintillation 
counter (Tri-Carb 2800TR, PerkinElmer, Waltham, MA) after deproteinization and 
drying. Tissue 2-[14C]DG and 2-[14C]DG-6-phosphate (2-[14C]DG-6P) were separated by 
ion-exchange chromatography. 
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Whole-body glucose turnover was determined at steady state from the ratio of 
the [3H] glucose infusion rate to the measured specific activity of plasma glucose108. 
Hepatic glucose production (HGP) was determined by subtraction of the glucose 
infusion rate from the whole-body glucose turnover108.  Skeletal muscle and adipose 
tissue glucose uptake was calculated from tissue 2-[14C]DG-6P content normalized 
against the area under the plasma 2-[14C]DG decay curve109.   
For brain glucose uptake calculations, isotope concentrations in regions of 
interest were measured from 20μm thick coronal serial sections after exposure to 
autoradiograph film via optical densitometry. Precise identification of the areas of 
interest (paraventricular nucleus of the hypothalamus (PVN), arcuate nucleus (ARC), 
ventromedial hypothalamus (VMH), hippocampus, cerebellum, and cortex) were 
accomplished by Nissl staining the desired areas (figure 4). Mean local rates of glucose 
utilization were calculated according to Sokoloff’s equation with rat rate constants, as 
mice rate constants have not been calculated110,111.  
 
Hyperinsulinemic-hypoglycemic mice clamps and c-fos immunostaining. 
Hyperinsulinemic (20 mU.kg-1.min-1) hypoglycemic (~30 mg/dl) clamps were performed 
as previously described27. Four month old mice underwent 2 hour hyperinsulinemic (20 
mU.kg-1.min-1) hypoglycemic (30 mg/dl) clamps as previously described27. A variable 
12.5% glucose infusion was used to carefully match blood glucose levels to 30 mg/dl. 
Blood samples were taken in the basal period and at the end of the clamp for hormone 
assays.  
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At the end of the 2 hr hypoglycemic clamp, mice were anesthetized with 
isofluorane and intracardially perfused with 0.01 M PBS (Sigma, Saint Louis, MO) 
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA).  The 
brains were immersed in 4% paraformaldehyde overnight and then cryoprotected in 
30% sucrose. Brain sections were then processed for c-fos immunostaining27. Four 
anatomically matched sections per animal were used to quantify c-fos immunostaining 
in the paraventricular nucleus of the hypothalamus (PVN).   
To test brain glucose sensing in a different model of GLUT4 knockout mice, 
hyperinsulinemic (120mU.kg-1.min-1) hypoglycemic (~35 mg/dl) clamps were performed 
in 5 week old whole body GLUT4 knockout mice created by crossing floxed GLUT4 
mice wth zona pellucida Cre expressing mice. The resultant KO mice lacked GLUT4 in 
all tissues, including the brain. During the hypoglycemic clamp, variable 50% glucose 
was infused to match blood glucose levels, as described above. 
 
Heat Stress.  Awake BG4KO and littermate control mice were exposed to an ambient 
temperature of 42°C for 60 minutes to induce heat stress. Arterial blood samples were 
taken from an indwelling cannula before and at the end of the heat stress period to 
measure epinephrine levels.  
 
Analytical measurments.  Blood glucose was measured by Ascensia Contour blood 
glucose monitors (Bayer) and plasma glucose was assayed by the glucose oxidase 
method and a spectrophotometer (BioTek Instruments, Inc., Winooski, VT).  Insulin 
levels were measured by enzyme-linked immunosorbent assay (ELISA) (Crystal Chem, 
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Chicago, Illinois).  Catecholamine analysis was performed by a single isotope-derived 
(radioenzymatic) method112. Radioimmunoassays were performed for glucagon (Linco 
Research, St. Charles, MO) and corticosterone (MP Biomedicals, Orangeburg, NY) 
measurements. 
 
Pharmacological inhibition of brain GLUT4 by indinavir (IDV).  Following recovery 
from intracerebroventricular cannula (Plastics One Inc, Roanoke, VA) and vascular 
implantation surgery, nine week-old male Sprague Dawley rats were subjected to a 
hyperinsulinemic (20 mU.kg-1min-1) hypoglycemic clamp (~45 mg/dl) as previously 
described113. Three hours prior to the start of, and for the duration of the clamp, 
indinavir (10μg/min; Merck, White-house City, NJ) or vehicle (artificial cerebrospinal 
fluid, aCSF) was infused into the third ventricle. Indinavir is a pharmacologic agent that 
has been shown to inhibit GLUT4 activity and transport in cell culture and hippocampal 
brain slices114-116. Arterial blood samples were taken in the basal period and at 45, 60, 
and 90 min into the hyperinsulinemic clamp. 
  
Electrophysiological studies. BG4KO and nestin-Cre positive littermate control mice 
(28-42 day old) were anesthetized and brains sectioned as previously described27. VMH 
GI neurons from both control and BG4KO mice were identified as reversibly depolarized 
and increased their action potential frequency and input resistance in response to a 
glucose decrease from 2.5 to 0.1mM. Input resistance was calculated by dividing the 
membrane voltage change (mV) by the current (pA). The effects of glucose and insulin 
(5nM) on action potential frequency, membrane potential and input resistance were 
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evaluated in current-clamp recordings (standard whole-cell recording configuration) 
from neurons in the VMH as previously described27,117,118. Current-voltage relationships 
were determined in the voltage-clamp recording mode using 10mV voltage steps from -
50 to -150mV from a holding potential of -60mV. 
 
Statistical analyses.  All data are presented as the mean  standard error of the mean 
(SEM). Statistical significance was set at p<0.05 and was determined by either 
Student’s t test or analysis of variance (ANOVA), as indicated.  
 
RESULTS 
Verification of brain-specific GLUT4 deletion 
Using the Cre-Lox system, brain specific GLUT4KO mice were created by 
crossing mice that express Cre driven by the nestin promoter with mice that have exon 
10 of GLUT4 flanked by loxP1,2,104. Four experimental groups were chosen for 
phenotypic analysis:  wild-type mice (WT); mice that have both GLUT4 alleles floxed 
(Lox); mice expressing Cre under the nestin promoter (Cre); and brain specific GLUT4 
knockout mice (BG4KO) that are homozygous GLUT 4 floxed and express Nestin Cre. 
To verify tissue specific deletion of GLUT4, GLUT4 protein concentration was measured 
by Western Blot analysis in the brain as well as the muscle, heart, and adipose tissue. 
BG4KO mice had a greater than 99% reduction in brain GLUT4 protein levels relative to 
WT, Lox, and Cre mice (Figure 2). Importantly, GLUT4 content in the heart, muscle, and 
adipose tissue of BG4KO mice was expressed at similar levels to the littermate controls 
(Figure 2), verifying brain specific GLUT4 knock-out. 
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To determine if deletion of brain GLUT4 altered expression of other brain glucose 
transporters, GLUT1 and GLUT3 protein expression were measured by Western blot.  
No significant difference in whole brain GLUT1 and GLUT3 protein levels were 
observed between BG4KO and littermate controls (Figure 3A,B). Furthermore, to 
confirm brain insulin signaling was unaltered by brain GLUT4 deletion, insulin receptor 
and pAKT protein were measured in the hypothalamus after a bolus IP insulin injection 
(3U/kg). There were no significant differences in insulin receptor or insulin stimulated 
pAKT protein expression between the groups (Figure 3C).  
 
Effect of Brain GLUT4KO on energy and glucose homeostasis. 
Body weight was measured weekly from 5 to 12 weeks of age. No significant 
difference in body weight was observed between Cre and BG4KO mice (Figure 4A). 
Intriguingly, both Cre and BG4KO mice had significantly reduced body weights 
compared to WT and Lox mice (Figure 4A). No significant difference in body weight was 
observed between WT and Lox mice (Figure 4). Thus, the expression of Cre itself 
reduced body weight consistent with a previous report119.   
The reduction in body weight was partly attributable to the reduction in body 
length. Crown-rump body length was measured at 12 weeks of age and, consistent with 
body weight, Cre and BG4KO were significantly shorter than WT and Lox mice (Figure 
4B). Brain mass and perigonadal fat pad mass were not significantly different between 
groups (Figure 4C). 
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Brain GLUT4KO does not affect fasting or fed blood glucose levels, but results in 
glucose intolerance. 
To assess the effect of the brain GLUT4KO on whole-body glucose homeostasis, 
fed and fasting glucose and insulin levels were measured in 12 week old mice on a 
normal chow diet. Fasting and random fed glucose levels were similar in all groups 
Figure 5A). Further, no difference in fasting or fed insulin levels were observed between 
groups (Figure 5B).  
To determine the role of brain GLUT4 in handling and responding to changes in 
glucose, dynamic tests were performed in overnight fasted mice. In response to an 
intraperitoneal glucose tolerance test (IPGTT; 2 mg/kg) BG4KO mice had significantly 
higher glucose excursions during the GTT than WT, Lox, and Cre littermates (Figure 
5C). To determine whether brain GLUT4 deletion also affected whole body insulin 
sensitivity, insulin tolerance tests (ITT, 1 U/kg) were performed in BG4KO and control 
mice. Despite the impaired glucose tolerance, BG4KO mice had similar reduction in 
blood glucose in response to insulin compared to littermate controls (figure 5D). To 
determine whether the impaired glucose tolerance in BG4KO mice was attributed to 
altered glucose stimulated insulin secretion (GSIS), plasma insulin levels were 
measured during the IPGTT. No difference in plasma insulin levels during the glucose 
tolerance test (Figure 5E) and no difference in first phase insulin secretion (Figure 5F) 
were observed between BG4KO mice and controls. 
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BG4KO have reduced insulin sensitivity and hepatic insulin resistance 
The effect of brain GLUT4KO on whole body insulin sensitivity was directly 
assessed by hyperinsulinemic-euglycemic clamps in BG4KO mice and controls. For 
statistical analyses, littermate control WT, Lox, and Cre mice were combined into one 
control group (CON) since no statistically significant differences were observed between 
these groups during the euglycemic clamp (e.g. glucose infusion rate, glucose kinetics, 
hepatic glucose production). Blood glucose levels during the baseline period and during 
the last hour of the clamp were not statistically different between BG4KO and CON 
(Figure 6A). Basal and clamp insulin were also not significantly different between the 
groups (data not shown). Interestingly, BG4KO mice required 22% lower glucose 
infusion rate (34±3 versus 43±2 mg/kg/min; p<0.02) to maintain euglycemia compared 
to controls, demonstrating whole-body insulin resistance (Figure 6B). Since BG4KO 
mice had similar basal glucose disposal (Rd) and similar insulin-stimulated increase in 
Rd as compared to CON mice, the defect in whole-body insulin sensitivity was not due 
to changes in glucose disposal (Rd) (Figure 7A). Consistent with similar Rd values 
between groups, no difference in tissue-specific glucose uptake in muscle or adipose 
tissue was observed between BG4KO and CON mice (Figure 7B, C). However, the 
ability of insulin to suppress endogenous glucose production (EGP) was only 48% in 
BG4KO as compared to 79% in CON mice (Figure 8A, B, p<0.02). To test if insulin 
resistance is due to impaired hepatic insulin signaling, phospho AKT (pAKT) and total 
AKT (tAKT) protein expression were analyzed by Western blot following IP insulin. In 
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response to insulin (3U/kg), hepatic pAKT protein expression increased similarly in 
BG4KO and control mice (Figure 8C, D).  
To determine whether deletion of GLUT4 in the brain results in altered glucose 
uptake, brain glucose uptake was measured using a radioisotope glucose uptake assay 
during a 2-hour hyperinsulinemic euglycemic clamp. Mean local rates of glucose uptake 
were calculated according to Sokoloff’s equation110,111. Brain glucose uptake was lower 
in BG4KO mice compared to control mice in select regions of the brain including the 
ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) (p<0.05 t-test) with a 
trend for decreased uptake in the paraventricular nucleus (PVN), hippocampus, 
cerebellum, nucleus tractus solitarus (NTS), and cortex (Figure 9A, B).  
 
Role of central GLUT4 on the counterregulatory response to hypoglycemia 
Pharmacological inhibition of central GLUT4 with indinavir attenuates the 
counterregulatory response to hypoglycemia   
To test whether brain GLUT4 is important in the counterregulatory response to 
hypoglycemia, indinavir (IDV), a GLUT4 inhibitor, or vehicle (artificial cerebrospinal fluid, 
aCSF) was infused into the third ventricle (10 µg/min) of chronically cannulated rats 
during a hyperinsulinemic hypoglycemic (~45 mg/dl) clamp. IDV is a pharmacologic 
agent that has been shown to inhibit GLUT4 activity and glucose transport 114-116. Blood 
glucose was not different in the basal period or during the hyperinsulinemic clamp 
period (Figure 10A). Further, no difference in epinephrine, norepinephrine, glucagon, 
and corticosterone was observed in the basal period. Interestingly, during the clamp, the 
glucose infusion rate required to maintain glucose at ~45 mg/dl was 44% higher in the 
32 
 
IDV-treated rats compared to controls (Figure 10B, P<0.05). The higher glucose 
infusion rates in IDV rats were associated with significantly attenuated counterregulatory 
response in these animals. Specifically, third ventricle infusion of IDV resulted in a 24% 
lower epinephrine response, a 22% lower norepinephrine response, and a 45% reduced 
glucagon response to hypoglycemia compared to controls (Figure 10C,D,E).   
 
Genetic deletion of brain GLUT4 impairs the counterregulatory response to 
hypoglycemia 
A genetic approach was used to further elucidate the role of brain GLUT4 in the 
counterregulatory response to hypoglycemia. Hyperinsulinemic hypoglycemic (~30 
mg/dl) clamps were performed in chronically cannulated, freely mobile BG4KO mice 
and their littermate controls. Basal glucose levels were similar and glycemia was 
carefully matched during the clamp period (Figure 11A). Insulin levels were also similar 
in the basal and clamp conditions (Figure 11B). Despite matched glucose levels, 
BG4KO mice required a lower glucose infusion rate to maintain ~30 mg/dl compared to 
Cre controls (315+162 vs 611+125 AUC; p < 0.05 ANOVA). However, glucose infusion 
rate was not statistically significantly different to WT and flox controls (data not shown). 
Basal epinephrine levels were similar in all groups (Figure 11C). During hypoglycemia, 
epinephrine levels rose similarly in the WT, Lox, and Cre mice (3133±600; 2902±560; 
2633±355 pg/ml, respectively; P=NS). However, the epinephrine response in BG4KO 
was significantly lower (1575±101 pg/ml) compared to littermate controls (P<0.05) 
(Figure 11C). Further, glucagon response to hypoglycemia was significantly attenuated 
in BG4KO mice (BG4KO 299±92 pg/ml; WT 650±57; Lox 597±74; Cre 651±39 pg/ml, p 
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< 0.001) (Figure 11D).  Norepinephrine and corticosterone responses to hypoglycemia 
were not significantly different between the 4 groups (Figure 11E, F).    
 
Impaired adrenomedullary response to stress is unique to hypoglycemia 
To test if the reduced epinephrine response to hypoglycemia in BG4KO mice 
was due to a generalized impairment in the adrenomedullary response to stress, 
epinephrine levels were measured in BG4KO and control mice subjected to 60 min of 
heat (42°C) stress. There was a significant increase in epinephrine and norepinephrine 
levels induced by heat stress but the increment was similar in both groups of mice 
(Figure 12A, B).     
  
Brain GLUT4KO reduces hypoglycemic-induced neuronal activation in the 
paraventricular nucleus 
To determine whether the impaired counterregulatory response in the BG4KO 
mice was associated with impaired hypothalamic neuronal activation, c-fos activation in 
response to hypoglycemia was measured in the hypothalamus following the 
hyperinsulinemic hypoglycemic clamps. Despite matched levels and duration of 
hypoglycemia, BG4KO mice had ~80% reduction in paraventricular nucleus (PVN) c-fos 
positive cells compared to controls (BG4KO  28 ± 17 versus WT 120 ± 20, Lox 138 ± 
19, Cre 141 ± 20 c-fos positive cells, p < 0.001) (Figures 13A, B).  
To further test the role of brain GLUT4 glucose sensing in response to 
hypoglycemia, whole body (zona-pellucida Cre driven) GLUT4 knockout mice 
underwent hyperinsulinemic (120mU.kg-1.min-1) hypoglycemic (~35 mg/dl) clamps.  
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Decreased neuronal activation during hypoglycemia was confirmed in these whole body 
GLUT4 knockout mouse model. Whole body GLUT4 knockout mice that underwent 2 
hours of hypoglycemia had reduced number of c-fos positive cells in the PVN (G4KO 
67.6±18 vs WT 142.1±28; p<0.05) and VMH (G4KO 22.6±9 vs WT 53.1±4; p <0.05; 
Figure 13C, D). 
 
Brain GLUT4KO causes impaired neuronal glucose sensing 
            In order to test whether the observed impaired counterregulatory response to 
insulin-induced hypoglycemia in BG4KO mice is a result of impaired brain glucose 
sensing or impaired insulin action, changes in membrane potential and input resistance 
of individual glucose inhibited (GI) neurons of the ventromedial hypothalamus (VMH) 
were measured using whole-cell current clamp recordings in brain slices both in the 
presence and absence of insulin. As expected for VMH GI neurons bathed in sufficient 
2.5mM glucose, action potential frequency in this basal state was low in recordings from 
control mice (0.43 +/- 0.12 Hz; N=14). Although, baseline action potential frequency 
tended to be higher in recordings of VMH GI neurons from BG4KO mice (0.75+/0.22; 
N=16) it did not reach statistical significance due to interneuron variation. On the other 
hand, VMH GI neurons from BG4KO mice exhibited significantly higher baseline input 
resistance (BG4KO: 1465+/-90M, N = 16; Control: 1042+/-77 M, N=14; P<0.01) and 
a depolarized membrane potential compared to GI neurons from control mice (BG4KO: 
-56+/-1mV; Control: -60+/-1mV; P<0.01). Increased excitability of VMH GI neurons in 
the absence of Glut4 is consistent with reduced glucose uptake. 
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            The glucose sensitivity of VMH GI neurons from control and BG4KO mice is 
illustrated by the whole cell current clamp recordings in figures 14A and 14B, 
respectively. No group differences were observed in GI neurons in response to a 
maximal glucose decrease from 2.5 to 0.1mM. In contrast, GI neurons from BG4KO 
mice had a significantly (p<0.0001) impaired change in membrane potential and input 
resistance (62% and 71% impairment, respectively) in response to a glucose decrease 
from 2.5 to 0.5mM (Figures 14A-D) indicating BG4KO mice have impaired glucose 
sensing.  
To determine whether the effects of insulin on VMH GI neurons are mediated by 
GLUT4, we evaluated the effects of 5nM insulin on the electrical properties of VMH GI 
neurons from BG4KO and control mice. Interestingly, insulin reversed the excitatory 
effects of 0.1mM glucose by decreasing input resistance and hyperpolarizing the 
membrane potential of VMH GI neurons to a similar extent in both genotypes (BG4KO 
% change: membrane potential -8+/-0.4, input resistance -14+/-0.7, n=7; control 
%change: membrane potential -9+/- 0.6, input resistance -16+/-1, n = 8; P=NS between 
genotypes) indicating insulin’s actions on these neurons is independent of GLUT4. 
Particularly interesting was that the current-voltage relationships obtained in voltage 
clamp indicate that the reversal potential for the effects of insulin and glucose were 
significantly (p<0.05) different, with the effect of insulin reversing near the K+ equilibrium 
potential (-94+/-4mV, n =4; Keq -99mV) and the effect of glucose reversing near the Cl
- 
equilibrium potential (-71+/-6, n=5; Cleq -60mV, figure 14E).  
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Figure 2. Brain-specific deletion of GLUT4.  (A)  Whole brain, gastrocnemius muscle, 
heart, and white adipose tissue (WAT) were harvested and homogenized for western 
blot analysis of GLUT4. GLUT4 was markedly reduced in the brain of BG4KO mice 
(BG4KO) compared to wild-type mice (WT), Lox expressing (Lox) and Cre expressing 
(Cre) mice. GLUT4 protein levels in muscle, heart, and WAT were similar between 
BG4KO and control mice. (B) Quantification of brain GLUT4 protein content.  BG4KO 
(black bar, n=11) had a greater than 99% reduction in brain GLUT4 levels compared to 
WT (white bar, n=6), Lox (horizontal hash, n=6), and Cre (slanted hash, n=6). *p < 
0.001 vs WT, Lox, and Cre mice. Data expressed as mean ± S.E.M. 
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Figure 3.  Brain GLUT1, GLUT3, pAKT, and insulin receptor protein expression 
was not altered in neuronal GLUT4 KO mice.  (A) Brain GLUT1 and (B) brain GLUT3 
protein expression as measured by Western blot analysis was not different in brain 
GLUT4KO mice (KO, black bar, n=5) versus wild-type (WT, white bar, n=4), Lox 
(horizontal hash, n=4), and Cre (slanted hash, n=4). C) Hypothalamic phospho-AKT 
(pAKT) and insulin receptor (IR ) protein expression were not different between 
BG4KO (gel lanes 3 and 4, black bar) and control mice (Cre, gel lanes 1 and 2, white 
bar) 30 minutes after an IP insulin (3U/kg) injection. Data expressed as mean ± S.E.M.  
n=4-5 per group.  
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Figure 4.  Brain GLUT4 knock-out did not affect body weight. (A) Body weight was 
similar between Cre (open triangle) mice and BG4KO (closed triangle) mice. Cre and 
BG4KO mice had slightly lower body mass compared to WT (open circle) and Lox 
(closed circle) mice. No difference in body weight was observed between WT and Lox 
mice. n=10-20 mice per group. (B) The reduction in body weight was attributable to 
smaller crown-rump length in Cre (slanted hash) and BG4KO (black bar) mice 
compared to wild type (open bar) and Lox (horizontal hash) mice. (C) Brain mass, fat 
pad mass, and heart weight were not significantly different between groups. n=5-7 mice 
per group. *p < 0.05 vs. WT, Lox, and Cre.  Data expressed as mean ± S.E.M. 
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Figure 5. Normal blood glucose but impaired glucose tolerance in BG4KO mice. 
(A) Male BG4KO (black bar) have similar fed and fasting blood glucose levels as well as 
similar fed and fasting plasma insulin levels compared to wild-type (open bar), Lox 
(horizontal hash), and Cre (slanted hashed). (B) BG4KO mice had similar fed and 
fasting blood insulin levels compared to controls. (C) Intraperitoneal glucose tolerance 
tests (IPGTT, 2 mg/kg) were performed in 12 week old male mice. BG4KO mice (closed 
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triangles) had significantly higher excursions in blood glucose compared to WT (open 
circles), Lox (closed circles), and Cre (open triangles) mice where indicated.  (D) No 
difference in the blood glucose was observed between BG4KO and control mice during 
an insulin tolerance test. (E) Insulin secretion during a glucose tolerance test was 
similar between BG4KO (closed triangle, n=4), wild-type (open circle, n=9), lox (closed 
circle, n=4) and Cre mice (open triangle, n=4) (p=NS). (F) In a separate study, first 
phase insulin secretion was measured during an intraperitoneal injection of glucose in 
BG4KO (closed triangle, n=7) and Cre controls (open triangle, n=8). First phase insulin 
secretion was not significantly different between groups.  *p < 0.05 vs. WT, Lox, Cre. 
Data expressed as mean ± S.E.M.  n=6-17 mice per group. 
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Figure 6. Euglycemic clamp glucose and glucose infusion rate. (A) Blood glucose 
during a hyperinsulinemic euglycemic clamp. No difference in blood glucose before or 
during the last hour of the clamp was observed between BG4KO (closed triangles) and 
control mice (CON, open triangles). (B) Despite matched blood glucose levels, BG4KO 
mice (closed triangles) required a significantly lower glucose infusion rate to maintain 
euglycemia compared to CON (open triangles) indicating insulin resistance (*p < 0.05, 
BG4KO vs. CON, all timepoints). Data expressed as mean ± S.E.M. n= 12-20 mice per 
group. CON= WT, Flox, and Cre mice.  
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Figure 7. Normal glucose disposal in BG4KO mice during a euglycemic clamp. (A) 
Rate of whole body glucose disposal at baseline and during the last 30 minutes of the 
hyperinsulinemic clamp was not significantly different between BG4KO (black bar) and 
CON (open bar). (B and C) 14C-2deoxyglucose determined glucose uptake specifically 
in muscle (B) and adipose tissue (C) was similar between BG4KO (black bar, n=7) and 
CON (white bar, n=17) during the hyperinsulinemic clamp. Data expressed as mean ± 
S.E.M. n= 12-20 mice per group. CON= WT, Flox, and Cre mice. All data expressed as 
mean ± S.E.M. 
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Figure 8. Hepatic insulin resistance in BG4KO mice during a euglycemic clamp. 
(A) Insulin suppressed endogenous glucose production (EGP) in BG4KO (black bar) 
mice to a lesser degree as compared to CON mice (white bar) (BG4KO 12.3±2.3 vs 
controls 5.1±2.3 mg/kg/min, *p < 0.04, ANOVA) B) Percent suppression of endogenous 
glucose production was reduced in BG4KO mice compared to controls (BG4KO 48±8% 
vs controls 79±8% suppression, *p < 0.02) during the last hour of the hyperinsulinemic 
clamp. C) Hepatic expression of phospho-AKT (pAKT), total AKT (tAKT) and -actin as 
shown by western blot after an IP bolus insulin (3U/kg) or saline injection. D) 
Quantification of hepatic pAKT shows that in both control (CON) and BG4KO mice 
hepatic pAKT increases in response to insulin (black bar) equally as compared to saline 
(white bar) in both groups (n=3 per group). Data expressed as mean ± S.E.M. n= 12-20 
mice per group. CON= WT, Flox, and Cre mice. All data expressed as mean ± S.E.M.   
44 
 
 
Figure 9. Reduced brain glucose uptake in BG4KO mice. Brain glucose uptake was 
measured using 14C-2-deoxyglucose autoradiography in mice that underwent a 
hyperinsulinemic euglycemic clamp.  (A) Precise identification of the areas of interest 
were accomplished by Nissl staining (left panels) and identifying the desired areas (i.e. 
ventromedial hypothalamus, (VMH), red dashed oval outline) and arcuate nucleus (red 
dashed triangular outline), and measuring the density of the outlined areas of interest on 
the exposed autoradiographic films (right panels). (B) Quantification of brain glucose 
uptake during euglycemia using Sokoloff’s equation in BG4KO (black bar, n=5) and 
control mice (white bar, n=5). Brain glucose uptake during the hyperinsulinemic 
euglycemic clamp was significantly reduced in BG4KO mice compared to control mice 
in ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) (*p < 0.05, t-test).  
Data expressed mean ± S.E.M.  
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Figure 10. Intracerebroventricular (ICV) infusion of an inhibitor of GLUT4 
transport, indinavir, reduced the counterregulatory response to hypoglycemia. 
Indinavir (IDV, closed circle, n=4) or artificial cerebrospinal fluid (aCSF, open circle, 
n=9) was infused for 90 min before and for the duration of a 90 min hyperinsulinemic 
hypoglycemic (~45 mg/dl) clamp in Sprague-Dawley rats. (A)  Blood glucose was 
precisely matched between rats treated with ICV infusions of either IDV or aCSF.  (B)  
Despite matched blood glucose levels, IDV treated rats (closed circle) required a 
significantly higher glucose infusion rate than control rats (open circle) (*p < 0.01, t-test 
of all timepoints).  The higher glucose infusion rate was attributed to the attenuated 
counterregulatory response to hypoglycemia due to the reduced GLUT4-mediated 
glucose sensing.  Epinephrine (C), norepinephrine (D), and glucagon (E) response to 
hypoglycemia was significantly reduced in IDV rats versus controls (* p<0.05 by ANOVA 
for all hypoglycemic timepoints for epinephrine and norepinephrine, AUC for glucagon).  
Data expressed mean ± S.E.M. 
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Figure 11. BG4KO mice have impaired counterregulatory response to 
hypoglycemia. BG4KO and control mice were subjected to hyperinsulinemic  
hypoglycemic (~30 mg/dl) clamps. (A) Blood glucose was not different before or during 
the clamp between BG4KO (closed triangle, n=5), wild-type (open circle n=5), Lox 
(closed circle, n=6), and Cre (open triangle, n=11). B) Insulin levels at basal and during 
the hypoglycemic clamp were not different between the groups. Wild type (open bar), 
Lox (horizontal hash), Cre (slanted hash) and BG4KO (black bar). (C and D) 
Epinephrine (C) and glucagon (D) responses to hypoglycemia were significantly 
reduced in BG4KO (black bar) mice compared to WT (open bar), Lox (horizontal hash), 
and Cre (slanted hash).  Norepinephrine (E) and corticosterone (F) levels during the 
hypoglycemic clamp were similar in all groups. *p < 0.05 versus WT, Lox, and Cre. Data 
expressed as mean ± S.E.M. n= 4-11 per group.   
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Figure 12.  Normal sympathoadrenal response to heat stress in brain GLUT4 
knock-out mice. Heat stress was induced to determine if the impaired 
counterregulatory response in BG4KO mice was specific for hypoglycemia. 
Norepinephrine (A) and epinephrine (B) levels increased during heat stress but there 
was no difference between the control (white bar) or BG4KO mice (black bar). Data 
expressed as mean ± S.E.M. 
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Figure 13. Brain specific and whole body GLUT4 KO mice have impaired 
hypothalamic neuronal activation during hypoglycemia. A and B) Nestin-Cre 
GLUT4 KO mice (A) Representative c-fos immunostaining of the hypothalamic 
paraventricular nucleus (PVN) in wild-type (WT) and BG4KO (KO) mice after 2 hours of 
hypoglycemia. (B) Quantification of c-fos immunostaining. The number of c-fos positive 
cells in the PVN was greatly reduced in BG4KO mice (black bar) compared to wild-type 
(open bar), Lox (horizontal hash), and Cre (slanted hash). *p < 0.05 versus WT, Lox, 
and Cre. n= 4-11 per group. C and D) Zona-Pellucida Cre GLUT4 KO mice (Whole body 
GLUT4 KO) (C) Immunohistochemistry of brain sections from WT (left) and G4KO 
(right) mice after 2 hours of a hypoglycemic clamp. C-fos positive staining is shown in 
the paraventricular nucleus (PVN) and ventromedial hypothalamus (VMH) of WT and 
G4KO mice. (D) Quantification of c-fos positive cells represented as total number per 
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mouse. G4KO mice (black bar) had significantly less c-fos positive cells in the PVN and 
VMH compared to WT mice (white bar). PVN: 68+18 vs. 142+28 (*p<0.04). VMH: 23+9 
vs. 53+4 (*p<0.02). n=6/group.  Data presented as mean+sem. 3V= third ventricle 
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Figure 14. Impaired glucose sensing in VMH GI neurons from BG4KO mice. Whole 
cell current clamp traces of VMH glucose-inhibited (GI) neurons in brain slices from 
nestin-cre control (A) and BG4KO (B) mice. The upward deflections represent action 
potentials, the resting membrane potential is given to the left of each trace, and the 
downward deflections are the voltage response to a constant current pulse. As 
compared to GI neurons from controls (white bars), GI neurons from BG4KO mice 
(black bars) had markedly impaired changes in membrane potential (C) and input 
resistance (D) when glucose levels were changed from 2.5 mM to 0.5 mM.  E) Current-
voltage relationship for a VMH GI neuron from control mice. The reversal potential for 
the effect of glucose (2.5 vs 0.1 mM glucose, upward dotted arrow) is close the 
theoretical Cl- equilibrium potential (ECl ~ -60 mV) suggesting that glucose activates a 
chloride channel. In contrast the reversal potential for the effect of insulin (0.1mM 
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glucose vs 0.1mM glucose + 5 nM insulin, downward dashed arrow) is near the 
theoretical K+ equilibrium potential (EK ~-99mV) suggesting that insulin activates a 
potassium channel.  *p < 0.001 versus control, data expressed as mean ± S.E.M. n=6-9 
per group. Performed in collaboration with Dr. Vanessa Routh, New Jersey Medical 
School. 
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Discussion 
 Based on immunohistochemical studies that identified GLUT4 in discrete areas 
of the central nervous system including the hypothalamus21, brain GLUT4 has been 
suggested to have a role in neuronal glucose sensing and whole body energy 
homeostasis. However, the physiological roles of central GLUT4 have remained 
unknown. This current study demonstrated a novel role of brain GLUT4 in the 
modulation of whole body glucose homeostasis, brain glucose sensing, and the 
counterregulatory response to hypoglycemia. 
 Tissue specific deletion of brain GLUT4 was accomplished by Cre-Lox 
technology. As expected, knockout of GLUT4 in the brain was virtually complete, while 
GLUT4 protein expression was still expressed at normal levels in heart, adipose tissue, 
and skeletal muscle. Further evidence for unaltered peripheral expression of GLUT4 
was noted by similar rates of whole body, adipose, and skeletal muscle glucose uptake 
in BG4KO and control mice during a hyperinsulinemic euglycemic clamp. 
 An interesting finding in this study was the expression of nestin-Cre alone 
resulted in a slight reduction in body weight and crown-rump length, similar to previous 
studies119,120, which may be attributed to Nestin-Cre’s mild hypopituitarism121. Since 
both BG4KO and nestin-Cre- mice express Cre+, the lack of difference in body weight 
between these two Cre+ groups indicate that deletion of brain GLUT4 did not have an 
effect on overall body weight. In consideration of this effect of nestin-Cre expression, all 
experiments were compared to Cre+/- littermates as a control group. Notably though, 
WT, lox, and Cre mice had similar metabolic phenotypes with regard to all other 
metabolic parameters assessed such as blood glucose levels, insulin levels, glucose 
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tolerance, insulin sensitivity, and counterregulatory responses. Thus, although nestin-
Cre expression resulted in a smaller size, it did not affect any other measured metabolic 
phenotype parameters. Importantly, a pharmacologic approach using indinavir to inhibit 
brain GLUT4 glucose transport during hypoglycemia produced similar results as the 
genetic approach indicating brain GLUT4 is important in brain glucose sensing. 
Consistent with a critical role for GLUT4 in mediating brain glucose sensing, the whole 
body G4KO mice, recently generated in the Kahn laboratory, also showed impaired 
neuronal activation in response to hypoglycemia. 
 Fasting and fed glucose levels were similar in BG4KO and control mice, 
suggesting little contribution of brain GLUT4 in regulating basal glucose homeostasis.   
When challenged with a glucose load during an IP glucose tolerance test, BG4KO mice 
had significantly higher blood glucose excursion than control mice indicating glucose 
intolerance.  Consistent findings of glucose intolerance have recently been reported in a 
distinct GLUT4 neuron ablation mouse model (Ren and Accili, Diabetes Suppl.1, A6, 
2011). Dynamic insulin tolerance tests, showed no difference in blood glucose lowering 
effect of insulin between BG4KO and control mice. The impaired glucose tolerance, but 
seemingly normal insulin sensitivity, could be attributed to diminished insulin secretion. 
However, glucose-stimulated insulin secretion was measured and no difference in 
insulin levels was seen between BG4KO and control mice after a glucose challenge. 
Thus, pancreatic β-cell responses to glucose remained unaffected by brain GLUT4 
deletion.   
 An insulin tolerance test is an imprecise measure of insulin sensitivity because 
with falling blood glucose levels, differential counterregulatory responses to 
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hypoglycemia (specifically an attenuated counterregulatory response) may mask the 
degree of insulin resistance. To directly assess insulin sensitivity, hyperinsulinemic-
euglycemic clamps were performed in BG4KO and control mice. BG4KO mice required 
a significantly lower glucose infusion rate to maintain euglycemia than controls, 
indicating insulin resistance. To better define the exact nature of the insulin resistance, 
glucose fluxes and glucose uptake into specific tissues were measured during the 
euglycemic clamp. Consistent with normal GLUT4 expression in peripheral tissues, 
BG4KO mice had a similar rate of glucose disposal as control mice. Further, glucose 
uptake in skeletal muscle and adipose tissue was not different between BG4KO and 
control mice. The insulin resistance in BG4KO mice can be attributed to hepatic insulin 
resistance as noted by the impaired ability of insulin to suppress endogenous glucose 
production. Since insulin stimulated AKT phosphorylation in the liver was found to be 
normal in BG4KO mice, hepatic insulin resistance in BG4KO mice seems to be 
independent of direct insulin signaling in the liver and is likely mediated via indirect 
mechanisms. Potential indirect roles of altered suppression of plasma free fatty acid 
levels in indirectly regulating EGP122 could not be determined as free fatty acids were 
not measured in this current study. Recent studies have demonstrated a role for central 
insulin signaling as an indirect mechanism by which insulin acts to suppress EGP, 
possibly via efferent vagal and sympathetic actions123,124. The absence of brain GLUT4 
in BG4KO mice may have limited the central actions of insulin to indirectly suppress 
EGP; although this is not due to proximal defects in hypothalamic insulin signaling as 
this study demonstrates hypothalamic insulin signaling is preserved in BG4KO mice, 
both in vivo and in vitro. One explanation for hepatic insulin resistance in BG4KO mice 
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may be that chronic adaptations in BG4KO mice led to altered neuronal development 
and plasticity altering the neuronal circuitry involved in glucose homeostasis125. 
Alternatively, reduced centrally mediated insulin inhibition of glucagon secretion may 
lead to a failure to suppress hepatic glucose production compared to controls126. 
Although glucagon was not measured during the euglycemic clamp, impaired regulation 
of glucagon secretion in the BG4KO mice was noted in the hypoglycemia studies. 
Regardless of the mechanism, the results indicate that insulin acts to regulate hepatic 
glucose production, at least in part, through brain GLUT4.    
 Several studies have suggested a relationship between central insulin action and 
GLUT416,21,127. When experimental conditions of hyperinsulinemia were studied that 
could maximize the potential difference in brain glucose uptake between BG4KO and 
control mice, brain glucose uptake into regions that normally express relatively high 
levels of GLUT4 was reduced in BG4KO mice. The reduced brain glucose uptake in 
BG4KO mice was expected to be relatively small because GLUT4 is normally 
expressed at a low level and only expressed in a fraction of all neurons16. Although 
recent studies have shown insulin-stimulated GLUT4 translocation occurs in 
neurons22,114,128 the current in vivo techniques are not of sufficient detail to resolve 
individual neuron glucose uptake. Further in vitro studies from neurons of BG4KO mice 
are needed to assess the role of GLUT4 neuron specific glucose uptake.  
 As GLUT4 and insulin receptors are co-expressed in up to 75% of glucose 
sensing neurons in the VMH16, brain GLUT4 may have an important role in the ability of 
neurons to sense and respond to changes in glucose. To test this possibility, the 
counterregulatory response to hypoglycemia was assessed in rodents that had central 
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GLUT4 inhibited pharmacologically (by indinavir) or genetically (BG4KO mice). Indinavir 
has been shown to selectively inhibit glucose transport through GLUT4 in both cell 
culture and in brain slices114-116. Both pharmacological inhibition as well as genetic 
deletion of central GLUT4 resulted in impaired epinephrine response as well as an 
attenuated glucagon response to hypoglycemia. Acute pharmacological inhibition of 
CNS GLUT4 was associated with a blunted counterregulatory response, demonstrated 
by an appropriately elevated glucose infusion rate during the hypoglycemic clamp. 
However, the paradoxically low glucose infusion rates in the BG4KO mice were likely 
due to their insulin resistance. Interestingly, since streptozotocin diabetic rats have 
reduced brain GLUT4 expression103 and impaired epinephrine and glucagon responses 
to hypoglycemia129, it may be that the impaired counterregulatory response to 
hypoglycemia associated with insulin deficient diabetes is mediated, at least in part, by 
decreased brain GLUT4.    
 To determine whether this impaired counterregulatory response was unique to 
hypoglycemia or a result of a more global impairment in the sympathoadrenal response 
to general stress, BG4KO and control mice were subjected to heat stress. The 
adrenomedullary responses to heat stress were identical in BG4KO and control mice 
indicating that BG4KO mice have an intact sympathoadrenal response to stress and 
that the impaired counterregulatory response in BG4KO is unique to hypoglycemic 
stress.   
 To determine whether the impaired counterregulatory response to hypoglycemia 
in the BG4KO mice was associated with impaired neuronal activation, c-fos staining 
was quantified in hypothalamic PVN of mice that underwent a hyperinsulinemic 
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hypoglycemic clamp130. In response to hypoglycemia, c-fos expression increased 
predominantly in the PVN, consistent with previous studies131. Notably, PVN c-fos 
activation to hypoglycemia was significantly reduced in BG4KO mice compared to 
controls. This finding of impaired c-fos activation in the PVN in response to 
hypoglycemia was independently confirmed in another whole body (including the brain) 
GLUT4 knockout model in which there was impaired neuronal activation in the PVN and 
VMH in response to hypoglycemia. The impaired hypoglycemia-induced c-fos activation 
in the brains of both of these GLUT4 knockout mouse models could represent reduced 
glucose sensing of PVN neurons or, given that the PVN receives input from other 
glucose sensing neurons in other regions of the brain, could represent an indirect 
reduction in afferent inputs from other brain regions. In either case, the brains of GLUT4 
knockout mice have a profound impairment in c-fos activation, consistent with other 
models of impaired glucose sensing and impaired counterregulation130. To more 
specifically identify the role of brain GLUT4 in glucose sensing within ventromedial 
hypothalamic neurons, electrophysiological studies were performed.  GI neurons from 
the VMH of BG4KO mice have an impaired response to decreasing glucose 
concentrations as measured by whole-cell clamp recordings thus supporting the 
findings that BG4KO mice have impaired hypothalamic glucose sensing.  
The simultaneous attainment of hyperinsulinemia and hypoglycemia with the 
hyperinsulinemic clamp studies do not allow us to determine whether reduced brain 
glucose sensing/uptake in the BG4KO mice is due to the absence of the acutely 
induced insulin-mediated neuronal GLUT4 translocation or reduced glucose transport 
due to the chronic absence of GLUT4, however our electrophysiology data support the 
58 
 
latter. First, in the absence of insulin, the finding of enhanced baseline excitability of 
VMH GI neurons from BG4KO mice is consistent with reduced intracellular glucose.  
Secondly, the addition of insulin equally inhibited VMH GI neurons from control and 
BG4KO mice. Finally, the current-voltage relationships indicate that insulin did not lead 
to activation of a Cl- channel as would be expected if insulin increased glucose 
uptake132. Interestingly, while insulin has been shown to inhibit hypothalamic AMPK133, 
this is unlikely to explain insulin’s effects on GI neurons because AMPK inhibition 
stimulates GI neurons by closing a Cl- channel134. Rather, the inhibitory effect of insulin 
on VMH GI neurons resulted from activation of a K+ channel. This insulin sensitive K+ 
channel is possibly the ATP-sensitive K+ channel since insulin has been reported to 
activate this channel in other hypothalamic glucose sensing neurons135,136. These data 
thus suggest that insulin inhibits GI neurons through a Glut4/glucose independent 
activation of a K+ channel.  
 It has previously been reported that neuronal insulin receptor knock-out (NIRKO) 
mice have a reduced content of brain GLUT4, and similar to the current BG4KO mice, 
NIRKO mice also demonstrate 1) glucose intolerance, 2) mild insulin resistance, 3) 
impaired epinephrine responses to hypoglycemia, 4) impaired neuronal activation to 
hypoglycemia, and 5) impaired glucose sensing in GI neurons of the VMH27,105,106. The 
similarities in the phenotype of NIRKO and BG4KO mice suggest that many of the 
actions of insulin in the brain are mediated by GLUT4. Paradoxically though, the current 
study demonstrates that hypothalamic insulin signaling was unaltered by GLUT4 
deletion and acute electrophysiological responses to insulin administration are 
independent of GLUT4. Collectively, it is hypothesized that the chronic lack of insulin 
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signaling or GLUT4 in the brains of NIRKO or BG4KO mice, respectively, that leads to 
the observed impairments in neuronal glucose sensing appears to be mechanistically 
distinct from the acute actions of insulin and/or GLUT4 translocation in regulating 
neuronal glucose sensing and the counterregulatory response to hypoglycemia.   
 As GLUT4 is expressed in diverse regions of the brain, BG4KO mice will be a 
useful tool in elucidating other potential roles of brain GLUT4 in cognition, learning and 
memory, and balance and coordination. In conclusion, central nervous system GLUT4 
plays an important role in regulating whole body glucose homeostasis, brain glucose 
sensing, and the counterregulatory response to hypoglycemia.   
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Chapter 3. Antecedent Glycemic Control Reduces Severe Hypoglycemia-Induced 
Neuronal Damage in Diabetic Rats 
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Abstract 
Brain damage due to severe hypoglycemia occurs in insulin treated people with 
diabetes.  This study tests the hypothesis that chronic insulin therapy that normalizes 
elevated blood glucose in diabetic rats would be neuroprotective against brain damage 
induced by an acute episode of severe hypoglycemia. Male Sprague-Dawley rats were 
split into 3 groups, 1) control, non-diabetic, 2) STZ-diabetic, and 3) insulin treated STZ-
diabetic. After 3 weeks of chronic treatment, all rats underwent acute 
hyperinsulinemic/severe hypoglycemic (10-15 mg/dl) clamps for 1 hour. Rats were 
subsequently analyzed for brain damage and cognitive function. Severe hypoglycemia-
induced 15-fold more neuronal damage in diabetic rats as compared to non-diabetic 
rats.  Chronic insulin treatment of diabetic rats, that nearly normalized glucose levels, 
markedly reduced neuronal damage induced by severe hypoglycemia. Fortunately, no 
cognitive defects associated with the hypoglycemia-induced brain damage were 
observed in any group. In conclusion, antecedent blood glucose control represents a 
major modifiable therapeutic intervention that can afford diabetic subjects 
neuroprotection against severe hypoglycemia-induced brain damage.  
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Introduction 
Severe hypoglycemia is a side effect of insulin therapy affecting ~40% of insulin 
treated diabetics29. Insulin treated diabetic patients experience an average of two 
symptomatic hypoglycemic episodes per week while severe hypoglycemia is 
experienced approximately once a year29. By depriving the brain of glucose, severe 
hypoglycemia can lead to brain damage. The cortex and hippocampus are especially 
sensitive to the brain damaging effects of severe hypoglycemia61. Deficits in learning 
and memory have been shown to be a direct consequence of severe hypoglycemia-
induced hippocampal neuronal damage51,53,54. Clinical research has shown that severe 
hypoglycemia induces cognitive deficits in some7,8,55,56 but not all studies57-59. Animal 
studies have shown that rats exposed to severe hypoglycemia perform worse in a 
Morris water maze60 indicating that brain damage is functionally related to poorer 
cognitive performance. Since uncontrolled diabetes magnifies the extent of severe 
hypoglycemia-induced brain damage61, it was hypothesized that chronic hyperglycemia 
associated with chronic insulin deficiency induces a mal-adaptive process that 
predisposes the brain to more extensive hypoglycemia-induced damage. Insulin has 
been shown to protect against ischemia-induced neuronal death both in vitro64 and in 
vivo67, but the potential neuroprotective effects of long-term insulin therapy for diabetic 
animals have yet to be examined in response to severe hypoglycemia induced brain 
damage.  
The aim of this study was therefore to determine if chronic insulin therapy 
resulting in the near normalization of glycemia could protect diabetic rats from 
hippocampal and cortical brain damage induced by a single episode of severe 
63 
 
hypoglycemia. It was also determined if this neuroprotective effect would also safeguard 
against hypoglycemia-induced deficits in learning and memory.  
 
Methods 
Animals and Surgery. Nine-week-old male Sprague-Dawley rats (Charles River 
Laboratories) were housed individually in temperature- and light-controlled environments 
fed ad libitum. All studies were done in accordance with and approved by the Animal 
Studies Committee at Washington University School of Medicine. In rats destined to 
undergo severe hypoglycemia, indwelling catheters were implanted under anesthesia in 
the left carotid artery and right jugular vein, as previously described61.  In control rats not 
destined to undergo hypoglycemia, the left carotid artery and right jugular vein were 
ligated under anesthesia. 
 
Induction of diabetes. Three days post-surgery, rats received intraperitoneal injections 
of either streptozotocin (STZ; 65 mg/kg, n = 37; Sigma) to induce diabetes or vehicle 0.1 
mM sodium citrate (Fisher Scientific) buffer for non-diabetic controls (CON, n = 18) 
(Figure 15). Some rats were injected a second time with STZ to ensure random glucose 
>300 mg/dl (Ascensia Contour BG monitors, Bayer HealthCare, Mishawaka, IN).  
(Figure 16A) 
 
Insulin treatment.  Eighteen of the diabetic rats were treated with subcutaneous insulin 
pellets (STZ+Ins; Linplant, ~2U/day, Lin Shin, Toronto, ON, Canada) to achieve blood 
glucose levels <250 mg/dl. If these rats were noted to have tail vein blood glucose >250 
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mg/dl, insulin (Lantus, 0-2.5U/day; sanofi-aventis, Bridgewater, NJ) was injected 
subcutaneously once daily.  If blood glucose values were below 50 mg/dl for 3 or more 
days, rats were excluded from the study.     
 
Hyperinsulinemic hypoglycemic clamp. Three weeks after STZ or vehicle injections, 
hyperinsulinemic (0.2 U·kg–1·min–1) hypoglycemic (10-15 mg/dl) clamps were performed 
in non-diabetic CON, uncontrolled STZ-diabetic, and chronically insulin treated STZ 
rats, as previously described60,61. At the start of insulin (Humulin R; Eli Lilly, Indianapolis, 
IN) infusion, all clamped rats received intravenous glucose (50% dextrose; Hospira, 
Lake Forest, IL) to match the rate of glucose decline observed in diabetic rats. All 
groups were precisely matched for duration (1 hour) and depth of hypoglycemia (10–15 
mg/dl). After 1 hour of severe hypoglycemia, insulin infusion was discontinued, and 
glucose was given to end hypoglycemia. Rats subjected to severe hypoglycemia were 
examined either for brain damage or behavioral testing (Figure 15).  
 
Fluoro-Jade B and hematoxylin-eosin staining. One week after the severe 
hypoglycemic clamps, anesthetized rats were intracardially perfused with 0.01 mol/l 
PBS (Sigma) followed by 4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA)60,61. Brains were immersed in 4% paraformaldehyde overnight and then 
cryoprotected in 30% sucrose. Beginning at 2.8 mm posterior to the bregma, four 
coronal cryostat sections (20 m), 120 m apart, were analyzed for neuronal damage 
by Fluoro-Jade B (Chemicon International) and hematoxylin-eosin (H-E) (Sigma) 
staining. Fluoro-Jade B is a well-characterized stain for degenerating neurons and was 
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performed as described by Schmued and Hopkins137. Fluorescent cells (Fluoro-Jade–
positive cells) were quantified in both hemispheres of the cortex and of the hippocampal 
structures CA1 and dentate gyrus. For each region of interest, data are expressed as 
the average number of Fluoro-Jade B positive (FJB+) cells per section.  
 
Behavioral testing. Consistent with other protocol designs52,54,138, histopathological 
outcomes were assessed 1 week following the hypoglycemic neuronal insult, while 
cognitive studies were performed 6–8 weeks later in a separate group of similarly 
treated rats. This later assessment of cognitive function is a more useful measure of 
clinical outcome and a better functional index of neuroprotection because it allows for a 
complete and integrated evaluation of ongoing damage and possible recovery139. After 
a 6- to 8-week recovery from the severe hypoglycemic clamp, CON (n=12), STZ (n=11), 
and STZ+Ins (n=12) rats, as well as a fourth group of sham operated negative control 
diabetic rats not subjected to hypoglycemia (STZ No Hypoglycemia, STZ-NH, n=10) 
were evaluated on a 1-hour locomotor activity test, a battery of sensorimotor measures, 
and on the Morris water maze (MWM) task60.  
One-hour locomotor activity test and sensorimotor battery. General locomotor 
activity and exploratory behavior were evaluated for 1 h in an open field (41 x 41 x 38.5 
cm high) constructed of Pleixglas and containing computerized photobeam 
instrumentation consisting of a 16 x16 matrix of photocell pairs (MotorMonitor; Kinder 
Scientific) to quantify ambulations (whole body movements) and vertical rearing 
frequency. As previously described140, the ledge, platform, 90o-inclined screen, and 
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walking initiation tests were conducted to measure balance, strength, coordination, and 
initiation of movement. 
Cognitive testing in the Morris water maze:  Spatial learning and memory were 
assessed for CON (n=12), STZ (n=11), STZ+Ins (n=12), and STZ-NH (n=10) groups 
using the Morris water maze test similarly to previously published methods140. Cued 
(visible platform, variable location) and place (submerged, hidden platform, constant 
location) trials were conducted to train rats to navigate to a submerged platform (1.5 cm 
below the surface of opaque water) in a round pool (118 cm diameter).  A computerized 
tracking system (ANY-maze, Stoelting Co., Wood Dale, IL) was used to quantify escape 
path length, latency, and swimming speeds which served as dependent variables.  Rats 
first received cued trials to determine if non-associative dysfunctions (sensorimotor or 
visual disturbances or alterations in motivation) were likely to affect performance in 
subsequent place trials. The cued condition involved conducting two sessions of three 
trials each (60-s maximum/trial) per day for two consecutive days during which the rats 
were trained to swim to the submerged platform marked (cued) by a visible pole with 3 h 
intervening between sessions.  The data were analyzed in blocks of three trials each for 
a total of four blocks. Three days later, the spatial learning capabilities of the rats were 
tested using the place condition in the water maze. This is a reference-memory based 
task where the rats were trained to learn the position of a submerged and hidden (since 
pole is removed) platform, which remained in the same location across all trials. The 
place trials protocol involved conducting two sessions of 3 trials each (60-s 
maximum/trial) per day for five consecutive days using a 3-h interval between sessions. 
The data were analyzed in blocks of six trials each (two daily sessions) for a total of 5 
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blocks. On days 3 and 5, a probe trial was conducted 1 h after the last place trial which 
involved removing the platform from the pool and quantifying the rats' search behaviors 
in the four pool quadrants for 30 s to evaluate retention of the platform location. Probe 
trial performance variables included: the number of times a rat passed directly over the 
platform location (platform crossings); the time spent in the target quadrant; and spatial 
bias which involved comparing the time spent in the target quadrant with time spent in 
each of the other quadrants. 
 
Statistics. All data are represented as means + sem.  Data were analyzed by one-way 
or repeated measures analysis of variance (ANOVA and rmANOVA, respectively).  The 
spatial learning data were analyzed using an ANOVA model containing one between-
subjects variable (Treatment: CON; STZ; STZ+Ins; and STZ-NH) and one within-
subjects (repeated measures) variable such as Blocks of Trials. For rmANOVAs, the 
Huynh-Feldt correction was used for all within-subjects effects containing more than two 
levels to help protect against violations of sphericity/compound symmetry assumptions 
underlying the rmANOVA model.  In addition, Bonferroni correction was used to help 
maintain prescribed alpha levels (e.g., 0.05) when multiple comparisons were 
conducted. 
 
Results 
Chronic insulin treatment nearly normalizes glucose level of diabetic rats. Rats 
that received streptozotocin displayed elevated blood glucose levels two days post 
injection and remained diabetic throughout the experiment compared to non-diabetic 
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controls (CON 100+1 mg/dl vs. STZ 484+10 mg/dl; Figure 16A). Insulin treatment 
reduced blood glucose levels to near normal (STZ+Ins 160+11 mg/dl). Sham operated 
diabetic rats that did not undergo severe hypoglycemia (STZ-NH) had similar glucose 
levels as the STZ group (STZ-NH 467+12 mg/dl). Prior to randomization, body weight 
did not differ between groups (CON: 302+10, STZ: 308+5; STZ+Ins: 302+7; STZ-NH: 
310+9g; Figure 16B). On the day of the severe hypoglycemic clamp, the non-diabetic 
and insulin-treated diabetic rats had an increase in body weight to 408+37 and 
387+14g, respectively, but 3 weeks of uncontrolled diabetes in the STZ and STZ-NH 
rats resulted in a failure to increase body weight (329+22 and 339+10g, respectively, 
p=NS compared to pretreatment; Figure 16B).  
 
Hyperinsulinemic-hypoglycemic clamp. All rats experienced the same degree of 
severe hypoglycemia (CON 12+0.3 mg/dl, STZ 13+0.7 mg/dl, STZ+Ins 12+0.3 mg/dl; 
Figure 17A). During severe hypoglycemia, animals lost their righting reflex, displayed 
seizure-like activity, and became minimally responsive. After one hour of severe 
hypoglycemia, glucose reperfusion was started so that animals reached euglycemia 
within 30 minutes (CON 159+48 mg/dl, STZ 181+31 mg/dl, STZ+Ins 172+48 mg/dl). 
Almost immediately animals regained consciousness and their righting reflex and 
seizure-like activity ceased. The animals were allowed to recover for 4 hours and then 
returned to their cages. The following day blood glucose levels were back to their 
respective values (CON 101+6 mg/dl, STZ 418+49 mg/dl, STZ+Ins 82+13 mg/dl).  
Overall mortality associated with the episode of severe hypoglycemia was 29%. 
Control rats had a mortality of 22% while STZ and STZ+Ins rats tended to have 
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increased mortality to 36% and 42%, respectively, but this did not reach significance 
(p<0.25, Fisher exact test, Freeman Halton extension; Figure 17B). 
  
Chronic insulin treatment decreases severe hypoglycemia-induced brain damage.  
One week following the acute severe hypoglycemic episode, rats were sacrificed and 
brains sectioned for neuronal damage using the marker Flouro-jade B which stains for 
degenerating neurons. In spite of equal depth and duration of hypoglycemia, diabetic 
rats had markedly increased (15-fold) brain damage in the hippocampus and cortex 
compared to non-diabetic rats (Figure 18A,B). In particular in the hippocampus, the 
CA1, CA3, and dentate gyrus regions had a 5-fold, 15-fold, and 45-fold increase in 
damage, respectively. Chronic antecedent insulin treatment reduced neuronal damage 
in diabetic rats (STZ+INS) in all regions to levels not significantly different from that of 
non-diabetic rats (Figure 18A,B).  
 
Severe hypoglycemia does not disrupt behavior. Severe hypoglycemia did not 
significantly impair locomotor or sensorimotor functions (Figure 19A,B) when tested 6-8 
weeks post-treatment (severe hypoglycemic clamp). An rmANOVA did not reveal any 
significant effects involving treatment on total ambulations (whole body movements) 
measured during the 1-hour locomotor activity test (Figure 19A) nor were any 
differences observed in vertical rearing frequency (not shown). Similarly, no 
performance differences between treatment groups were observed with regard to any 
measure on the battery of sensorimotor tests. For example, although the CON group 
tended to perform not as well as the diabetic groups in terms of being able to remain on 
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a small elevated platform, a one-way ANOVA showed no significant differences among 
groups on this sensorimotor test (Figure 19B) nor on other sensorimotor measures of 
balance (ledge), strength (90º inclined screen) or initiation of movement (walking 
initiation) out of a small delineated space (not shown).  
 Interestingly, we also found no general performance differences between 
treatment groups on the learning and memory indices quantified during testing in the 
Morris water maze. Specifically, no effects involving treatment were found following 
rmANOVAs conducted on the escape path length (Figure 19C), latency, or swimming 
speed data (not shown) during the cued (visible platform location) trials. These results 
suggest that there were no visual, sensorimotor, or motivational disturbances in any of 
the groups that would compromise swimming performance and thus confound 
interpretation of the subsequent place trials data. With regard to the acquisition (spatial 
learning) performance of the treatment groups during the place trials (Figure 19D), an 
rmANOVA conducted on the path length data yielded a significant Treatment by Blocks 
of Trials interaction, (F12,64 = 2.54; p=0.011).  Subsequent comparisons showed that this 
was mostly due to increased path length in the STZ NH group versus the STZ-Ins 
(p=0.036) or the CON (p=0.037) groups during the first block of trials only, but not 
thereafter. A significant Treatment by Blocks of Trials interaction (F12,64 = 2.32; p=0.016) 
was also found for escape latency (not shown), although only the comparison between 
the STZ NH versus STZ+Ins groups were significantly different ( p=0.017). Note that 
although the comparisons cited here for block 1 revealed certain large (p<0.05) 
differences between treatment groups, none of the “P” values were less than the 
Bonferroni corrected level (p=0.05/4= 0.0125). Thus, it is appropriate to conclude that 
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the performance of the treatment groups did not differ at any time with regard to path 
length or latency during acquisition (place trials). Consistent with the general lack of 
differences between treatment groups during the place trials were comparable 
performance levels observed among groups during the probe trials. For example, one-
way ANOVAs revealed non-significant treatment effects with regard to time in the target 
quadrant during probe trial 1 (mid-acquisition) (Figure 19F) and platform crossings (not 
shown). In addition, all groups demonstrated significant spatial bias for the target 
quadrant that had contained the hidden platform as evidenced by each group spending 
significantly more time in the target quadrant compared to times spent in each of the 
other quadrants (p<0.01). Similar results were found for the same variables during the 
second probe trial conducted 1 hour after the last place trial on day 5 (not shown). 
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Figure 15. Experimental protocol for analysis of brain damage and cognitive 
function after severe hypoglycemia. After recovery from arterial and venous 
cannulation, rats were injected with streptozotocin (STZ) or vehicle (Con, n=18). Three 
days later insulin treatment was started in a subset of the STZ diabetic rats (STZ+Ins, 
n=15) by implanting an insulin pellet and starting insulin injections as needed to 
maintain blood glucose <250 mg/dl. About 3 weeks later, hyperinsulinemic (0.2 U·kg–
1·min–1) severe hypoglycemic (10-15 mg/dl) clamps were performed in all rats except a 
group of diabetic rats that were not subjected to the  severe hypoglycemic clamp (STZ-
NH). After the episode of severe hypoglycemia, either neuronal damage was assessed 
by Flouro jade B and H&E staining one week later, or rats were studied 6-8 weeks later 
with sensorimotor and cognitive testing. Brain damage study: CON (n=6), STZ (n=6), 
STZ+Ins (n=6); Cognitive testing study: CON (n=12), STZ (n=13), STZ+Ins (n=12), 
STZ-NH (n=10) 
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Figure 16. Glucose levels and body weight during the brain damage and cognitive 
testing protocols. A) Blood glucose levels throughout the experiment. The non-
diabetic (CON, closed circle) rats had glucose levels of ~100 mg/dl. After STZ injection, 
STZ diabetic rats (open circle) and STZ diabetic rats no hypoglycemia(NH, open 
triangle) had glucose levels of >450 mg/dl. The diabetic rats chronically treated with 
insulin (STZ+Ins, closed triangle) group had markedly improved blood glucose levels 
(160 + 11 mg/dl) throughout the experimental timeline. HYPO= day of severe 
hypoglycemic clamp B) The non-diabetic (CON) and insulin treated diabetic (STZ+Ins) 
groups increased their body weight over time while the STZ and STZ-NH groups did not 
increase their body weight. Note: Time axis not to scale. Wk= week; n= 10-18 per 
group. Data shown as mean + SEM. 
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Figure 17. Severe hypoglycemic clamp glucose and mortality. A) Glucose levels 
during the hyperinsulinemic/hypoglycemic clamp. Insulin infusion decreased glucose 
levels over a 4 hour period in the CON (n=18), STZ (n=19), and STZ+Ins (n=18) groups 
until glucose reached 15 mg/dl. Glucose was clamped between 10-15 mg/dl for 1 hour 
and then hypoglycemia was terminated with increased glucose infusion throughout a 4 
hour recovery period. B) Mortality associated with severe hypoglycemia was 22% in 
CON, 36% in STZ, and 42% in STZ+Ins treated rats but the difference was not 
significant (p<0.25). Note: Time axis not to scale. 
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Figure 18. Severe hypoglycemia induced brain damage. A) Representative Fluoro-
Jade B (top 3 rows) and hematoxylin and eosin (H&E –bottom 3 rows) staining of the 
cortex and hippocampal structures, CA1, CA3 and the dentate gyrus (DG), one week 
following an episode of severe hypoglycemis in non-diabetic (CON), uncontrolled STZ-
diabetic (STZ), and chronically insulin treated STZ (STZ+Ins) rats. Neuronal damage is 
indicated with Fluoro-Jade B positive cells (green fluorescence) or by pyknotic cells 
(H&E staining, black arrows). Blue= dapi, nuclear stain. B) Brain damage was markedly 
elevated in the cortex and hippocampus in STZ (white bar) rats compared to controls 
(black bar).  STZ+Ins (diagonal hash bar) reduced this damage in both regions.  (*p< 
0.05 ANOVA n=6 per group). Data shown as mean + SEM. 
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Figure 19. Severe hypoglycemia does not produce impairment in behavioral and 
cognitive functions.  A) There were no significant effects involving treatment (severe 
hypoglycemia) on general activity as measured by total ambulations (whole body 
movements) during a 1-h locomotor activity test.  B) Although the CON group tended to 
perform not as well as the diabetic groups in terms of being able to remain on a small 
elevated platform, there was no significant differences among groups on this 
sensorimotor test. C) Groups did not differ in escape path length during the cued (visible 
platform location) trials.  D) A rmANOVA conducted on the path length data during the 
place (spatial learning) trials yielded a significant Group (Treatment) by Blocks of Trials 
interaction, (*p=0.011). This was mostly due to increased path length in the STZ NH 
group versus the STZ-Ins (†p=0.036) or the CON (††p=0.0369) groups during the first 
block of trials only, but not thereafter. E) No differences among groups were observed in 
swimming speeds during the place trials.  F) Groups performed similarly in terms of time 
in the target quadrant during probe trial 1 (mid-acquisition). In addition, all groups 
demonstrated significant spatial bias for the target quadrant that had contained the 
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hidden platform as evidenced by each group spending significantly more time in the 
target quadrant compared to times spent in each of the other quadrants (*p<0.01).  
TGT= target quadrant, LFT= left quadrant, OPP= opposite quadrant, RGT= right 
quadrant; Performed in collaboration with Dr. David Wozniak, Washington University in 
St. Louis. 
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Discussion 
 Studies investigating the potential neuroprotective role of insulin often do not 
differentiate the acute versus chronic effects of insulin therapy. The present findings 
show that while acute insulin-induced hypoglycemia can cause brain damage, chronic 
insulin treatment in diabetic rats to restore normoglycemia is markedly neuroprotective 
and significantly reduces the extent of severe hypoglycemia-induced brain damage.  
It was hypothesized that the uncontrolled diabetic rats that displayed markedly 
elevated hypoglycemia-induced brain damage would perform much worse than other 
rats tested, and that the marked neuroprotective effects of chronic insulin therapy would 
mitigate against demonstrable deficits in cognitive performance. As with clinical studies, 
animal studies of hypoglycemia and cognitive performances are variable. However, it 
was somewhat surprising that Morris maze testing was unable to demonstrate 
differences in cognitive performances between the groups. Our previous Morris maze 
studies in normal rats60 showed rapid improvements in escape path lengths and 
latencies in sequential trial tests, very similar to the currently tested groups of rats, 
suggesting that all of the current groups of rats performed equally well with no 
detectable cognitive deficit. It is suspected that the extent of brain damage achieved in 
the current studies did not reach a high enough threshold to cause demonstrable 
deficits in learning/memory performances as determined by Morris maze testing. 
Previous experiments of longer duration of hypoglycemia that cause 3-6 fold more brain 
damage than observed in the current study indeed do result in demonstrable deficits in 
Morris maze testing60. Although considered, the relatively high mortality in the current 
series of rats precluded hypoglycemia experiments of longer duration. Interestingly, a 
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dissociation between severe hypoglycemia-induced brain damage and detectable 
cognitive deficit is consistent with clinical studies in which severe hypoglycemia alters 
brain structure4 yet detectable cognitive deficits are seen in some4,8 but not all59 studies.  
Consistent  with a previous report from our lab revealing that diabetic rats are 
more susceptible to severe hypoglycemia-induced death141, mortality due to severe 
hypoglycemia tended to be increased in both the uncontrolled diabetic (STZ) and 
insulin-treated diabetic (STZ+Ins) rats compared to controls. However, since the 
difference was not significant, future research is focusing on how diabetes per se might 
increase risk of severe hypoglycemia-induced death. While the cause of death in the 
current experiments is unknown, it is hypothesized that severe hypoglycemia induces 
fatal cardiac arrhythmias which is further discussed in chapter 4. 
Hypoglycemia has been shown to induce neuronal cell death via a cascade of 
molecular events, including increased release of glutamate, calcium, zinc, and reactive 
oxygen species, leading to cell death142. The mechanism by which hypoglycemia-
induced neuronal damage was markedly augmented in diabetic rats was not directly 
assessed in these studies although many potential mechanisms exist. 1) The greater 
net drop in glycemia experienced in the diabetic rats (i.e. from 484 to 13 mg/dl) may 
have exacerbated brain damage. 2) The decreased number of brain glucose 
transporters103 and altered glucose transport and metabolism143 may have led to the 
increased susceptibility to brain damage in the diabetic rats. 3) An up-regulation of 
glutamate leading to calcium overload may have enhanced neuronal death in diabetic 
rats144. 4) STZ-diabetic rats show a down regulation of cortical NMDA receptors145, 
which may be particularly important given the role of excess glutamate in mediating 
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hypoglycemia-induced neuronal damage146. 5) Following the hypoglycemic episode, the 
effects of chronic hyperglycemia may have been toxic to vulnerable neurons resulting in 
increased brain damage147.  
In the absence of severe hypoglycemia, uncontrolled diabetes (induced by 
streptozotocin) does not result in brain damage as shown by a previous report61. 
Therefore, in the current studies, diabetic rats not subjected to severe hypoglycemia 
(STZ-NH) were not analyzed for brain damage. 
The mechanism by which chronic insulin therapy afforded neuroprotection 
against brain damage cannot be precisely determined in this model. It was 
hypothesized that chronic insulin deficiency may predispose the diabetic brain to greater 
hypoglycemia-induced damage. Studies in ischemic brain injury models are consistent 
with the notion that insulin directly acts in the brain to afford neuroprotection64,67. 
Alternatively, since the down regulation of brain glucose transporters by chronic 
hyperglycemia103 may predispose the brain to profound neuroglycopenia in response to 
acute severe hypoglycemia, it may be that the correction of chronic hyperglycemia 
alone could be neuroprotective. Another possible mechanism for the neuroprotective 
effect of chronic insulin therapy could be related to the preconditioning effect of 
recurrent hypoglycemia60. Although rats that displayed recurrent hypoglycemia were 
specifically excluded from the study, we cannot rule out the possibility that in an attempt 
to achieve near normalization of blood glucose levels, some of the insulin treated 
diabetic rats might have had episodes of undetected antecedent hypoglycemia which 
could have preconditioned the brain and protected it against the subsequent severe 
hypoglycemic episode60. Regardless of the mechanism, the effect was profound. The 
81 
 
10-15 fold reduction in hypoglycemia-induced brain damage indicates that antecedent 
blood glucose achieved with chronic insulin therapy is a major beneficial therapeutic 
intervention that provided the diabetic rats significant neuroprotection. 
For patients and clinicians, the choice to pursue an intensive insulin regime as a 
therapeutic approach to realize the established long-term microvascular benefits 
associated with tight glycemic control, has to be weighed against the increased risk of 
severe hypoglycemia and associated adverse outcomes including brain damage.  In this 
study, chronic insulin treatment in diabetic rats that lead to a near normalization of 
glucose levels, markedly reduced the extent of brain damage induced by severe 
hypoglycemia. These intriguing findings indicate that chronic insulin therapy that 
improved glycemic control, paradoxically, rendered the diabetic rats more prone to, but 
less vulnerable to, an episode of severe hypoglycemia. In conclusion, antecedent blood 
glucose control represents a major modifiable therapeutic intervention that can afford 
diabetic subjects neuroprotection against a subsequent episode of severe 
hypoglycemia-induced brain damage. 
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Chapter 4. Sudden Deaths due to Lethal Cardiac Arrhythmias during Severe 
Hypoglycemia are Mediated by Sympathoadrenal Activation 
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Abstract 
 
For people with insulin treated diabetes, severe hypoglycemia can be lethal. 
Potential mechanisms by which hypoglycemia can lead to sudden death are not well 
understood. To study how severe hypoglycemia can be fatal, 1-3 hour hyperinsulinemic, 
severe hypoglycemic (10-15 mg/dl) clamps were performed in Sprague-Dawley rats 
with simultaneous continuous electrocardiogram recording. With a goal towards 
reducing severe hypoglycemia induced mortality, the hypotheses tested were: 1) 
antecedent glycemic control impacts ability to survive an episode of severe 
hypoglycemia, 2) by limiting hypokalemia, potassium supplementation could limit 
cardiac arrhythmic deaths, 3) by preventing central neuroglycopenia, brain glucose 
infusion could prevent hypoglycemia associated arrhythmic deaths, and 4) by limiting 
the effects of sympathoadrenal activation during hypoglycemia, adrenergic blockers 
could provide a survival advantage by preventing lethal cardiac arrhythmias. Mortality 
rates associated with severe hypoglycemia were worsened by diabetes, but recurrent 
antecedent hypoglycemia markedly improved survival. Potassium supplementation 
trended to reduce mortality in non-diabetic and diabetic rats. Severe hypoglycemia 
caused numerous cardiac arrhythmias including premature ventricular contractions, 1st, 
2nd, and 3rd degree heart block, and ventricular tachycardia. Intracerebroventricular 
glucose infusion reduced cardiac arrhythmias and mortality due to severe 
hypoglycemia. Beta adrenergic blockade reduced cardiac arrhythmias and completely 
abrogated deaths due to severe hypoglycemia. In conclusion, severe hypoglycemia 
induced sudden death was preceded by fatal cardiac arrhythmias. Mortality was entirely 
prevented by blocking the effective sympathoadrenal response. It is concluded that 
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brain neuroglycopenia and the marked catecholaminergic sympathoadrenal 
counterregulatory response are the primary mediators of fatal cardiac arrhythmias 
induced by severe hypoglycemia. 
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Introduction 
The rate of sudden death in young people with Type 1 diabetes is 10-fold higher 
than age matched controls78. Sudden nocturnal deaths account for up to 27% of all 
unexplained deaths in people with Type 1 diabetes75,77. The aptly named “dead in bed 
syndrome” identifies otherwise healthy young individuals with Type 1 diabetes that were 
found dead in bed with no clear cause of death69-71,73-78. It has been speculated that 
their deaths were due to excess insulin administration and resultant severe 
hypoglycemia70-74,76,77,80. However, the mechanisms by which severe hypoglycemia can 
be lethal is unclear.  
The brain requires a constant supply of glucose to function normally. During 
hypoglycemia, lack of glucose supply to neurons can lead to confusion, brain damage81, 
seizures82,83 and if hypoglycemia is low enough for long enough, it may be fatal. Indeed, 
6-10% of deaths in people with Type 1 diabetes are directly attributable to 
hypoglycemia59,148,149. It has been hypothesized that acute onset cardiac arrhythmias 
contribute to severe hypoglycemia-induced sudden death. Clinical studies using 
electrocardiograms (ECG) have found that cardiac arrhythmias associated with QTc 
prolongation occur during moderate hypoglycemia85-89. Prolongation of the QTc interval 
can lead to increased risk of fatal cardiac arrhythmias91-93. It remains undetermined to 
what extent severe hypoglycemia induced cardiac arrhythmias are mediated by central 
neuroglycopenia versus systemic factors affecting cardiac tissue.  
In the setting of insulin-induced hypoglycemia, both the insulin-induced 
decrement in potassium levels and the counterregulatory-induced increase in 
catecholamine levels have been speculated to contribute to arrhythmias88,97,98. It has 
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been shown previously that potassium or beta blockers can reduce cardiac arrhythmias 
in patients during moderate hypoglycemia (~45 mg/dl)88. It is well established that 
increased catecholamine levels can lead to ventricular arrhythmias95,96. However, it 
remains to be determined whether the prevention of hypokalemia and/or blocking the 
actions of the catecholamines protect against lethal arrhythmias and cardiorespiratory 
arrest during the setting of severe hypoglycemia.   
In order to determine preventable causes of death during severe hypoglycemia, 
protocols described below describe how experimental rats were monitored for cardiac 
arrhythmias and mortality during an episode of severe hypoglycemia during which time 
putative protective agents were administered.  
 
Methods 
Animals. Nine-week-old male Sprague-Dawley rats (Charles River Laboratories) were 
housed individually in a temperature- and light-controlled environment fed ad libitum 
with standard rat chow diet and water. All studies were done in accordance with and 
approved by the Animal Studies Committee at Washington University School of 
Medicine. 
 
Implantation of arterial and venous catheters and ECG leads.  Nine week old male, 
Sprague Dawley rats were anesthetized with an intraperitoneal injection of Ketamine 87 
mg/kg and Xylazine 2.6 mg/kg.  A micro-renathane® (Braintree Scientific, Boston, MA) 
catheter was inserted into the left carotid artery for sampling access and two catheters 
were implanted into the right jugular vein for infusions. To maintain patency, at the time 
87 
 
of implantation catheters were filled with a 40% polyvinylpyrrolidone (Sigma) in heparin 
(1000 USP U/ml) solution (Baxter Healthcare Corporation, Deerfield, IL). In some 
studies, at the time of surgery one electrocardiogram (ECG) wire lead was placed in the 
right supraclavicular fossa and another wire lead was placed exterior to the lower left rib 
cage, in the mid axillary line, to approximate clinical lead II position. ECG wire leads 
were secured and sutured in place to the underlying muscle. A reference lead was 
placed subcutaneously over the back. The free ends of the three wire leads and vessel 
catheters were buried subcutaneously on the animal’s back for easy retrieval on the day 
of the clamp. Rats were allowed to recover for 4-10 days. All rats had restored their pre-
operative weight before being subjected to the hypoglycemic clamp.  
 
Hyperinsulinemic-severe hypoglycemia clamp. After an overnight fast, vascular 
catheters and ECG leads were externalized under brief isoflorane anesthesia. Animals 
were allowed to rest for 1.5 to 2 hours before basal samples were taken. Awake, 
unrestrained rats were subjected to hyperinsulinemic (0.2 U · kg−1 · min−1) severe 
hypoglycemic (10-15mg/dl) clamps for 3 hours unless otherwise noted. Rats had free 
access to water. Insulin (Humulin R; Eli Lilly, Indianapolis, IN) and glucose (50% 
dextrose; Hospira, Lake Forest, IL) were co-infused intravenously to lower blood 
glucose to 10-15 mg/dl over a period of 2 to 2 ½ hours. During the first hour of insulin 
infusion, glucose levels were maintained at ~70 mg/dl in order to assess the effects of 
hyperinsulinemia on the electrocardiogram, in the absence of profound hypoglycemia. 
Arterial blood samples were obtained every 15 minutes to measure blood glucose 
(Ascensia Contour blood glucose monitors, Bayer HealthCare, LLC, Mishawaka, IN). All 
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experimental groups were precisely matched for duration and depth (10-15 mg/dl) of 
hypoglycemia. Mortality due to severe hypoglycemia was determined by cessation of 
breathing.  
Blood samples were taken during the basal period and at various times 
throughout the severe hypoglycemic clamp for epinephrine, norepinephrine, glucagon, 
and insulin measurements. Insulin was measured by ELISA (Crystal Chem, Downers 
Grove, Il). Glucagon was measured by RIA (Millipore, Billerica, MA). Plasma 
epinephrine and norepinephrine levels were determined by a single isotope derivative 
(radioenzymatic) method112. Blood pressure (Noninvasive BP monitor, Columbus 
instruments, Columbus, OH) was measured by tail cuff in the basal period and every 15 
minutes during severe hypoglycemia in select studies. 
 
Arterial blood gas and electrolytes. Blood samples were taken at various timepoints 
throughout the clamp for analysis of potassium, oxygen, carbon dioxide, calcium, and 
pH on an ABG machine (pHOx Plus C, Nova Biomedical, Waltham, MA). Respiration 
was calculated as breaths per minute by visibly counting breaths. 
 
Seizures. Episodes of seizure-like behavior were noted during the severe hypoglycemic 
clamps. Tonic-clonic seizure-like behavior was visually noted by characteristic brief (5-
10 seconds) neck extensions, tonic stretching, uncontrolled limb movements, and 
spontaneous spinning61,150. The incidence of seizure-like behavior was quantified for 
each rat during the clamp period. A subset of rats also had electroencephalogram 
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(EEG) recording (XLTEK Video EEG System, Oakville, Ontario) to analyze brain waves 
before, during, and after hypoglycemia-induced seizures. 
Study 1: Overall mortality analysis in control, diabetic and recurrently 
hypoglycemic experiments. Control (n=123), diabetic (n=95), and recurrent 
hypoglycemic (n=27) rats that underwent 1 hour of severe hypoglycemia60,61,146 were 
analyzed for mortality.  
Diabetes. Approximately two weeks before the severe hypoglycemic clamp, diabetes 
was induced by intraperitoneal injection of streptozotocin (STZ; 65 mg/kg; Sigma) as 
previously described61. Control non-diabetic rats received vehicle injections of 0.1 mM 
sodium citrate (Fisher Scientific) buffer. Some rats were injected with a second dose of 
STZ to ensure random glucose >300 mg/dl (Ascensia Contour BG monitors, Bayer 
HealthCare, Mishawaka, IN).   
Recurrent hypoglycemia. For three consecutive days before the severe hypoglycemic 
clamp, moderate hypoglycemia (25-40 mg/dl) was recurrently induced in non-diabetic 
rats with injections of subcutaneous regular human insulin (Lilly, Indianapolis, IN; 6 U/kg 
on day 1; 5 U/kg on day 2; and 4 U/kg on day 3) as previously described60. Control rats 
received saline injections. Severe hypoglycemic clamps were performed on the 4th day. 
 
Study 2: Potassium supplementation. Potassium (KCl, 0.375 mEq/ml, Hospira, Lake 
Forest, Il) was infused with saline at 4 μl/min. Non-diabetic rats either received (n=12) or 
didn’t receive (n=15) potassium and diabetic rats either received (n=28) or didn’t receive 
potassium (n=45) throughout a hyperinsulinemic/severe hypoglycemic clamp, as 
described above. 
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Study 3: Cardiac arrhythmias in control experiments 
ECG studies. To explore the possibility of arrhythmias as a possible cause of death, 
control non-diabetic rats (n=6) underwent severe hypoglycemic clamps for 90 minutes 
as described above, with continuous ECG recording (ADI Powerlab 26T, Colorado 
Springs, CO). ECG analyses included heart rate, QTc length, and other arrhythmias 
(ADI LabChart Pro 7). QTc was calculated using Bazett’s formula151. Cardiac 
arrhythmias were analyzed for incidence and frequency. For frequency analysis, 
arrhythmias were counted individually and divided by the amount of time spent in 
severe hypoglycemia (either 180 or minutes or time of death). 
 
Study 4: ICV glucose infusion. Using a digital stereotactic neurosurgery apparatus 
and under continuous 1% isofluorane anesthesia, intracerebroventricular (ICV) 
cannulas (internal cannula 31g, outer guide cannula 24g, 9.5mm depth; Plastics One 
Inc, Roanoke, VA) were placed on the skull in the midline -2.8 mm posterior to bregma. 
Screws were affixed to the bare skull and glue was applied (SNAP, Parkell Inc, 
Edgewood, NY) to fasten the cannula in place. Rats were allowed to recover 1 week 
post ICV surgery before implantation of vascular catheters and ECG leads as described 
above. On the day of the clamp, the ICV cap was removed and a cannula primed with 
either 2mM D-glucose (n=9) (Sigma, St. Louis, MO) or 2mM D-mannitol (n=9) (Sigma) 
was placed in through the guide cannula. Glucose or mannitol (as a control) were 
infused at 0.1 l/min via the internal ICV cannula at the start, and throughout, the 
hyperinsulinemic/severe hypoglycemic clamp, as described above. Correct ICV cannula 
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placement in the third ventricle was confirmed in all rats studied by post mortem staining 
with Evan’s blue dye.   
 
Study 5: Adrenergic blockade. On the day of the clamp, after a 2 hour basal period,  
(prazosin, Sigma, 1 receptor blocker, 1 mg/ml dissolved in sterile distilled water and 
infused at 1 l/min) and  (propranolol, Sigma, 1/2 receptor blocker, 1 mg/ml infused 
at 2.5 l/min) blockers were infused intravenously either concurrently (n=13) or 
individually (n=5-6) starting 30 minutes prior to insulin infusion and continued throughout 
the severe hypoglycemic clamp, as described above. Saline was infused in controls 
(n=12). The drug doses chosen were based on previous studies describing the use of 
adrenergic blockers in rats98 and by pilot studies. 
 
Statistical analyses. All data are represented as mean+sem. Analysis of variance 
(one- and two-way where appropriate), repeated measures ANOVA, and student’s t-test 
were used to determine significance. Holm-Sidak’s and Dunn’s method were used for 
post-hoc analyses. Fisher exact test with the Freeman-Halton extension was used to 
determine significance for mortality and arrhythmia incidence. Significance was 
determined by p<0.05. 
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Results 
Study 1: Overall mortality analysis in control, diabetic and recurrently 
hypoglycemic experiments  
In order to understand how diabetes and recurrent hypoglycemia might affect the 
ability to survive an episode of severe hypoglycemia, rats were placed into 3 groups: 1) 
control, non-diabetic, 2) uncontrolled diabetic (streptozotocin), and 3) recurrent 
moderate hypoglycemia (3 days of glucose 25-40 mg/dl for 3 hours). Basal morning 
glucose levels for control non-diabetic rats were 88±5 mg/dl. Uncontrolled STZ-diabetic 
rats had a fasted basal glucose of 348±37 mg/dl. Rats that underwent recurrent 
hypoglycemia had a basal glucose of 74±2 mg/dl.  All three groups of rats underwent a 
hyperinsulinemic/severe hypoglycemic clamp for 1 hour. During severe hypoglycemia, 
mean glucose levels were similar for control (11.5±0.21mg/dl), diabetic 
(12.1±0.24mg/dl), and recurrent hypoglycemia (11.9±0.41mg/dl) rats. The epinephrine 
response to hypoglycemia was normal in diabetic rats, but epinephrine was blunted in 
recurrent hypoglycemia rats (2001±241 vs 3487±474 pg/ml in controls60). All rats lost 
their righting reflex, went into a coma, and experienced brief seizure like activity. 
Analysis of severe hypoglycemia induced mortality rates was found to be 21% in 
control, non-diabetic rats and increased to 36% in diabetic rats (p<0.05; Figure 20A). 
Interestingly, rats that had been previously treated with the recurrent moderate 
hypoglycemia protocol had markedly less mortality (only 4%) during their severe 
hypoglycemic clamp (p<0.05; Figure 20A). Differences in death rates were 
hypothesized to be due to hypokalemia, neuroglycopenia, and/or the sympathoadrenal 
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response, each of which could have increased susceptibility to cardiac arrhythmias and 
are each individually tested in the subsequent experiments.  
 
Study 2: Potassium supplementation  
In order to determine if cause of death due to severe hypoglycemia resulted from 
hypokalemia, potassium was supplemented in non-diabetic and diabetic rats during a 1 
hour severe hypoglycemic clamp. Morning basal glucose levels were similar for rats that 
either received or did not receive potassium supplementation. Control rats had basal 
glucose levels of 127±7 mg/dl and 116±12 mg/dl, respectively. Basal glucose levels for 
diabetic rats were 479±77 mg/dl and 394±54 mg/dl, respectively. Mean glucose levels 
during severe hypoglycemia were not different among the non-diabetic rats that did 
(12.6±1.18mg/dl) or did not (12.5±0.76mg/dl) receive potassium or the diabetic rats that 
did (12.1±0.84mg/dl) or did not (13.4±0.39 mg/dl) receive potassium. Potassium levels 
decreased during severe hypoglycemia in both non-diabetic rats (from 4.2+0.15 to 
2.9+0.06 mmol/l) and in diabetic rats (from 4.0+0.11 to 2.9+0.23 mmol/l) that did not 
receive potassium (Figure 20B). With potassium supplementation, potassium levels 
were maintained during severe hypoglycemia compared to basal in non-diabetic 
(4.4+0.26 to 3.9+0.38mmol/l) and diabetic (4.5+0.25 to 3.8+0.47mmol/l) rats (Figure 
20B). Mortality associated with severe hypoglycemia trended to be reduced with 
potassium supplementation compared to rats that did not receive potassium 
supplementation in both non-diabetic (from 33% to 8%) and diabetic (from 44% to 25%) 
rats, but this did not reach significance (p<0.08; Figure 20C).  
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Study 3: Cardiac arrhythmias in control experiments 
We observed that sudden death in the setting of severe hypoglycemia seemed to 
be related to electrolyte (i.e. potassium) concentration. Since hypokalemia can be pro-
arrhythmic, in order to determine if severe hypoglycemia induced mortality is mediated 
by cardiac arrhythmias, control, non-diabetic rats (n=6) were subjected to 
hyperinsulinemic/severe hypoglycemic clamps with continuous ECG recording. Glucose 
levels were gradually decreased and glucose was held between 10-15 mg/dl for 90 
minutes (Figure 21A). With this longer duration of severe hypoglycemia, all the rats died 
(Figure 21B).  
Following insulin administration and during the initial period of moderate 
hypoglycemia, heart beats per minute (bpm) remained normal as compared to the basal 
state (Figure 21C). It was not until severe hypoglycemia that heart rate increased. 
Additionally, during severe hypoglycemia, multiple cardiac arrhythmias were noted, 
discussed below. Heart rate was variable toward the end of severe hypoglycemic due to 
the few survivors towards the end of the clamp and due to the multiple types of cardiac 
arrhythmias that tended to, in some cases, reduce the heart rate while at other times 
increase the heart rate. Periods of tachycardia (>400 bpm) as well as bradycardia (<300 
bpm) were noted with increasing frequency with the duration of severe hypoglycemia.  
Widening of the QTc complex as noted on the ECG rhythm, represents 
dispersion of ventricle depolarization and repolarization and is known to be pro-
arrhythmic. Marked QTc prolongation was observed shortly after insulin infusion when 
glucose levels were only in the moderate hypoglycemia range (47+6 mg/dl) (Figure 
21D). As compared to basal QTc of 122+2ms, peak QTc during severe hypoglycemia 
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was 172+8ms, indicating a 40% increased ventricular depolarization and repolarization 
phase (p<0.001).  
Epinephrine and norepinephrine increased during severe hypoglycemia 
compared to the basal period (p < 0.001; Figure 21E,F; Table 1). Plasma epinephrine 
peaks around the start of severe hypoglycemia and decreases as severe hypoglycemia 
prolongs indicating possible adrenal failure. Plasma norepinephrine gradually increases 
during severe hypoglycemia. 
In the setting of hypoglycemia, QTc prolongation, hypokalemia, and elevated 
catecholamines can increase risk of cardiac arrhythmias. Cardiac arrhythmias did not 
occur during early moderate hypoglycemia. It was only following 15 minutes of severe 
hypoglycemia did premature ventricular contractions (PVCs) and narrow complex 
second degree heart block (Mobitz II) started to be noted as the initial cardiac 
arrhythmias (Figure 22). Frequency of PVCs and 2nd degree heart block were 1.4+0.7 
and 2.1+0.8 per minute, respectively (Figure 23A). In addition, other cardiac arrhythmias 
typically seen during severe hypoglycemia were premature atrial contractions (PACs) 
and 1st degree heart block (Figure 22). Occasionally, brief (<10 seconds) runs of 
ventricular fibrillation and non-sustained ventricular tachycardia were noted, but these 
rhythms were not noted to precede sudden death (Figure 23B). During severe 
hypoglycemia, a consistent pattern of sequential progression of arrhythmias that 
preceded cardiorespiratory arrest was carefully noted. With prolonged hypoglycemia, 
more frequent and longer duration second degree heart block as well as higher grade 
second degree heart block (ie, atrial:ventricular conduction ratio of 4:1) were noted.  
Following second degree heart block, the most commonly noted terminal arrhythmias 
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were third degree heart block (complete atrioventricular dissociation), characterized by 
a terminal bradycardic ventricular rhythm (Figure 22).  
Arterial blood gas and electrolytes. Oxygen and carbon dioxide levels remained normal 
throughout the experiment until just prior to death, where oxygen levels decreased and 
carbon dioxide levels increased (Figure 23C, Table 1). 
 Potassium levels decreased during severe hypoglycemia compared to the basal 
period (p< 0.05, Table 1). In the moribund phase, potassium levels increased. Following 
a similar pattern, pH levels also remained normal throughout the clamp and only 
decreased just prior to death (p<0.05, Table 1). Calcium and bicarbonate levels did not 
change during severe hypoglycemia (Table 1). 
Blood pressure. Blood pressure increased from 105+14/60+2 during the basal period to 
177+16/93+9 mmHg during severe hypoglycemia (Figure 23D). Blood pressure 
remained elevated until immediately prior to death when it suddenly decreased.  Before 
becoming immeasurable, the last recorded blood pressure was 77+10/59+10 mmHg. 
Seizures. Seizure-like activity was noted in all rats that underwent 
hyperinsulinemic/severe hypoglycemic clamps. Seizure-like activity was quantified by 
counting the number of characteristic, brief (<5 sec), myoclonic convulsions. A subset of 
rats also had simultaneous EEG recording during the clamp. During severe 
hypoglycemia, EEG tracings showed characteristic high-amplitude slow waves and 
EEG isoelectricity coincided with a non-responsive comatose state (Figure 24).  Also 
during severe hypoglycemia, high frequency high amplitude spikes of increased 
electrical activity were noted during seizures.  Given that all severely hypoglycemic rats 
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had seizures, yet only a fraction of severe hypoglycemic rats died, it was not surprising 
that no correlation was found between seizure activity and mortality. 
 
Study 4: ICV glucose infusion  
In order to understand and to isolate the extent to which neuroglycopenia during 
hypoglycemia mediates sudden death, glucose was infused into the 3rd ventricle of the 
brain during the severe hypoglycemic clamps to prevent brain neuroglycopenia. 
Compared to controls, ICV glucose infusion reduced mortality due to severe 
hypoglycemia from 86% to 33% (p < 0.05; Figure 25A). Systemic blood glucose was 
similar during severe hypoglycemia in ICV mannitol (MAN, n=9) and ICV glucose (GLU, 
n=9) infused rats (11.7+0.1 vs 12.2+0.2 mg/dl, respectively; p = 0.13; Figure 25B; Table 
2). Despite matched glucose levels, ICV glucose infused rats required a higher 
peripheral glucose infusion rate (5.4+0.56 mg/kg/min; p < 0.005) during severe 
hypoglycemia compared to MAN (4.1+0.41 mg/kg/min; Figure 25C). Insulin levels were 
comparable between both groups during basal and severe hypoglycemia (Table 2). 
ECG analyses. During severe hypoglycemia, heart rate was significantly lower in the 
GLU group compared to the MAN group (p<0.05, Figure 25D). Mean heart rate 
increased in the ICV mannitol group from 373+4 in the basal to 414+9 BPM during 
severe hypoglycemia (p < 0.01) while ICV glucose infusion prevented this rise in heart 
rate (basal:357+4 vs. severe hypoglycemia:357+8 BPM). Mortality incidence was 
associated with duration of sinus tachycardia (heart rates greater than 400 BPM; Figure 
26A); however, ICV glucose infused rats had decreased mortality compared to ICV 
mannitol infused rats despite more than 30 minutes of tachycardia. 
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QTc increased during severe hypoglycemia compared to basal in both MAN and 
GLU groups with no significant differences between the groups (p = 0.14; Figure 25E). 
Greater QTc length was associated with an increased mortality risk (Figure 26B). 
However, mortality rate was lower in ICV glucose infused rats compared to ICV 
mannitol infused rats despite QTc prolongation. 
Cardiac arrhythmias were absent in 25% of the ICV glucose infused rats. 
Frequencies of PVCs and second degree heart block were nonsignificantly reduced with 
ICV glucose infusion compared to ICV mannitol infusion (p<0.07 and p<0.06, 
respectively; Figure 26C,D). Incidence of 3rd degree heart block was decreased in the 
GLU group compared to the MAN group (p<0.05; Figure 26E). Third degree heart block 
was observed just before death in all rats that died in both groups. Rats that lived did 
not experience third degree heart block suggesting that third degree heart block was the 
terminal fatal arrhythmia associated with severe hypoglycemia. Other life threatening 
arrhythmias such as ventricular tachycardia leading to ventricular fibrillation was 
witnessed in 33% of the MAN group and 0% of the GLU group but this difference was 
not significant (Figure 26F). 
Epinephrine increased in both the MAN and GLU groups during severe 
hypoglycemia to 1926+320 and 2155+448 pg/ml, respectively, with no difference 
between the groups (Table 2). Norepinephrine increased in the MAN group during 
severe hypoglycemia (1441+646 pg/ml) but this response was attenuated in the GLU 
group (464+48 pg/ml) (p< 0.05; Figure 25F, Table 2). Interestingly, just prior to death, 
norepinephrine was significantly elevated in ICV glucose infused rats (p<0.001 vs 
severe hypoglycemia; Table 2). 
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Arterial blood gas and electrolytes. Potassium levels significantly decreased during 
severe hypoglycemia in both the MAN and GLU groups compared to basal (Table 2). 
Potassium during severe hypoglycemia was significantly lower in the GLU group 
(p<0.05).  
Oxygen and carbon dioxide levels did not change during severe hypoglycemia 
(Table 2). Just before respiratory arrest in MAN and GLU rats that died, oxygen 
decreased to 35+10 and 18+17%, respectively, and carbon dioxide increased to 47+3 
and 53+5 mmHg, respectively (Table 2).  
Mean respiration during severe hypoglycemia for the MAN and GLU groups was 
not different (85+4.4 and 78+4 breaths per minute, respectively; Table 2) but ICV 
glucose infused rats had lower respiration during severe hypoglycemia compared to 
basal. Respiration decreased just prior to death in the MAN and GLU groups, 
respectively (p <0.01 vs basal; Table 2).  
Seizure occurrence was 100% in the MAN group but only 78% in the GLU group; 
however, this was not statistically significantly different (data not shown).  
 
Study 5: Adrenergic blockade  
In order to test the hypothesis that the sympathoadrenal response increases risk 
of fatal cardiac arrhythmias during severe hypoglycemia, rats had adrenergic receptors 
blockers infused during a 3 hour hyperinsulinemic/severe hypoglycemic clamp. Mortality 
associated with severe hypoglycemia was 33% in control rats (n=12) while both 
combined  and  blocker infusion (, n=13) and  blocker infusion alone (n=5) 
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completely prevented death (p < 0.029; Figure 27A).  blocker infusion alone had no 
effect on mortality (50%; n=6).  
Glucose levels during severe hypoglycemia were equally matched in control, 
combined / blocker,  blocker alone, and  blocker alone infused rats (11.7+0.2, 
12.3+0.3, 11.6+0.5, and 12.4+0.5 mg/dl, respectively; Figure 27B). Consistent with a 
blunted effective counterregulatory response, glucose infusion rate was increased 
during severe hypoglycemia in / blocker infused rats (4.87+0.24mg/kg/min; p < 0.01; 
Figure 27C) compared to controls (3.3+0.41mg/kg/min). Glucose infusion rates during 
severe hypoglycemia were nonsignificantly increased in  blocker infused rats (4.5+0.65 
mg/kg/min) and nonsignificantly decreased in  blocker infused rats (2.1+0.61 
mg/kg/min) compared to controls (p = 0.12; Figure 27C). Insulin levels were not 
significantly different between the groups (Figure 28A). 
ECG analyses. Heart rate was variable throughout the clamp. During severe 
hypoglycemia mean heart rate was 331+5, 225+5, 339+9, and 198+4 BPM in CON, / 
blocker,  blocker, and  blocker infused rats, respectively (Figure 27D). /and  
blocker infused rats had significantly lower heart rates during severe hypoglycemia 
(p<0.05, ANOVA). While soon after the start of insulin infusion and glucose lowering the 
 blocker infused rats had a higher heart rate compared to controls, during severe 
hypoglycemia heart rate was similar to controls. The lower heart rate in the / blocker 
and  blocker infused rats indicates that the effects of beta blockade were working to 
prevent the rise in heart rate seen in control rats. Additionally, increased heart rate in  
blocker infused rats indicates that the alpha blockade treatment was effective. In the 
control and  blocker groups, sinus tachycardia (heart rate greater than 400 BPM) was 
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experienced in all of the rats that died with more than 30 minutes of tachycardia 
resulting in 100% mortality (Figure 28B). Treatment with  blocker, and combined / 
blocker completely abrogated the hypoglycemia induced tachycardia and mortality. 
Therefore, sinus tachycardia is a predictor of mortality in these experiments and 
prevention of tachycardia was associated with a mortality benefit. 
From baseline levels, there was significant QTc prolongation during severe 
hypoglycemia in control (105+6 to 163+2ms),  blocker (129+3 to 210+5ms), and  
blocker (117+3 to 164+2 ms) infused rats (p < 0.001) but QTc prolongation was blunted 
in / blocker (99+2 to 134+3ms; p < 0.001) infused rats compared to controls (Figure 
27E). QTc prolongation was associated with an increased risk of mortality in the control 
and  blocker rats (Figure 28C). In control and  blockade rats, markedly increased 
QTc prolongation lengths of more than 200ms resulted in 33% and 67% mortality, 
respectively. Interestingly, the  blocker infused rats had increased QTc prolongation 
very similar to control rats (Figure 27E) yet had a 100% survival rate indicating that QTc 
prolongation alone may not be a direct mediator of lethality associated with severe 
hypoglycemia, but rather may be a harbinger of impending mortality. QTc prolongation 
appears to be a marker of severe hypoglycemia, but is not in itself sufficient to trigger 
the more lethal types of cardiac rhythms.  
While the control and  blocker infused rats experienced PACs, PVCs, and 1st, 
2nd, and 3rd degree heart block, the / blocker and  blocker infused rats mostly only 
experienced a few PACs, PVCs and 2nd degree heart block but with less frequency. 
PVCs occurred in 25% of the rats with / blocker infusion but only during or after a 
visible seizure whereas heart block occurred in only 8% of the rats (p<0.001). Single 
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and  blocker infused rats had reduced arrhythmias overall compared to controls. 
Frequency of PVCs was reduced in combined / blocker and  blocker infused rats 
compared to controls (p<0.001; Figure 29A). Although  blocker infused rats trended to 
have lower frequency of PVCs, there was no significant difference compared to 
controls. Frequency of 2nd degree heart block was significantly reduced in combined / 
blocker (0.0004+0.0004 per minute; p< 0.001) and trended to be reduced in  blocker 
(0.08+0.06 per minute), and  blocker (0.17+0.18 per minute) infused rats compared to 
controls (1.1+0.43 per minute; Figure 29B). Third degree heart block was prevented in 
/ blocker and  blocker infused rats but was only significantly different with / 
blocker infusion (p< 0.024; Figure 29C). Rats with  blocker infusion experienced 
similar incidence of 3rd degree heart block as controls. These results indicate that 
although  blocker infusion is sufficient to prevent death, both  and  adrenoreceptors 
need to be blocked to nearly completely prevent arrhythmias. 
Epinephrine and norepinephrine significantly increased during severe 
hypoglycemia compared to basal in control, / blocker,  blocker, and  blocker 
infused rats (Figure 29D,E); however, while measurable in the peripheral circulation, the 
actions of epinephrine and norepinephrine were dually blocked with combined / 
blockade or partially blocked with single  or blockade. Epinephrine peaked during the 
first 30 minutes of severe hypoglycemia and was significantly higher in  blocker infused 
rats (5610+599pg/ml) compared to controls (2603+353pg/ml; p<0.004) and / blocker 
infused rats (3097+396; p<0.011; Figure 29D). Epinephrine levels in  blocker infused 
rats (3335+716 pg/ml) were not different from controls. Norepinephrine was significantly 
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increased in the  blocker group (2720+435pg/ml; p<0.001) compared to the control 
(667+164 pg/ml), / blocker (591+69 pg/ml), and  blocker groups (1006+312 pg/ml; 
Figure 29E).  
Glucagon increased during severe hypoglycemia compared to basal in control, 
/ blocker, and  blocker infused rats with no significant difference in  blocker infused 
rats. Glucagon was significantly higher in  blocker infused rats compared to all three 
groups (p<0.001 for AUC; Table 3). Elevated glucagon is consistent with the elevated 
norepinephrine in the  blocker group which may be acting on beta adrenergic 
receptors on pancreatic alpha cells to stimulate glucagon secretion at a higher rate 
compared to controls. 
Arterial blood gas and electrolytes. Mean potassium levels decreased in all groups 
during severe hypoglycemia although potassium was significantly higher in  blocker 
infused rats (p <0.01, Table 3). The similar degree of low potassium between the 
control, / blocker, and  blocker infused rats indicates that in the setting of severe 
hypoglycemia, hypokalemia alone is not sufficient to cause cardiac arrhythmias 
because / blocker infusion prevents arrhythmias in the presence of hypokalemia.  
Oxygen saturation and carbon dioxide levels were normal for all groups 
throughout the clamp (Table 3). Control rats had a mean respiration during severe 
hypoglycemia of 76+3 breaths/min (Table 3). Respiration decreased in the / blocker 
and  blocker infused rats to 51+2 and 54+2 breaths/min, respectively (p < 0.001), while 
 blocker infused rats had similar respiration (65+8 breaths/min) compared to controls. 
Decreased respiration was consistent with higher carbon dioxide levels in / blocker 
and  blocker infused rats versus controls (p < 0.001; Table 3). Respiration decreased 
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in the control and  blocker infused rats just prior to death with a concomitant decrease 
in oxygen and increase in carbon dioxide levels (Table 3).  
Seizure like activity was witnessed in 100% of the control,  blocker, and  
blocker infused rats but only 71% of the / blocker infused rats (data not shown). 
However, this difference was not significant and no correlations were found between 
seizure-like activity and mortality.  
Blood pressure. Mean systolic blood pressure during severe hypoglycemia for control, 
/ blocker,  blocker, and  blocker infused rats was 133+14, 140+10, 129+8, and 
112+4 mmHg with  blocker infusion resulting in a significantly lower blood pressure 
(p<0.001; Figure 28D). Mean diastolic blood pressure during severe hypoglycemia was 
91+16, 90+9, 92+8, and 77+4 mmHg, respectively, with a significantly lower blood 
pressure in  blocker infused rats (p<0.001; Figure 28E). Most importantly blood 
pressure did not suddenly increase or decrease prior to death in any of the groups 
indicating that blood pressure is maintained throughout severe hypoglycemia. 
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Figure 20. Severe hypoglycemia induced mortality in diabetic, non-diabetic, 
recurrently hypoglycemic rats, and the effects of potassium supplementation 
(studies 1 and 2). A) Analysis of morality associated with severe hypoglycemia 
revealed 21% mortality in non-diabetic control rats (n=123). Mortality was increased in 
diabetic rats to 36% (n=95) and decreased to 4% (n=27) in rats that underwent 
recurrent hypoglycemia prior to severe hypoglycemia (*p<0.05 Fisher exact test, 
Freeman-Halton extension). B) Potassium levels in rats that had no potassium 
supplementation (No K+, non-diabetic: white bar, diabetic: diagonal slash) versus rats 
with potassium supplementation (K+, non-diabetic: black bar, diabetic: horizontal slash) 
both in the basal state and during severe hypoglycemia. Rats without supplementation 
had potassium levels significantly decrease during severe hypoglycemia while rats with 
supplementation maintained normal potassium during severe hypoglycemia. Potassium 
levels in nondiabetic rats without potassium (white bar), nondiabetic rats with potassium 
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(diagonal slash), diabetic rats without potassium (black bar), diabetic rats with 
potassium (horizontal slash). C) Potassium supplementation in nondiabetic and diabetic 
rats trended to reduce severe hypoglycemia-induced mortality from 33 to 8% (n=12-15) 
and 44 to 25% (n=28-45), respectively, but this did not reach significance. Data 
expressed as mean+sem. 
  
107 
 
 
Figure 21. Severe hypoglycemic clamp in control experiments (study 3). A) 
Glucose levels of control, nondiabetic rats during a severe hypoglycemic clamp. With 
insulin infusion and careful glucose infusion, plasma glucose levels are decreased over 
a 2 ½ hour period to 15 mg/dl (time 0). Severe hypoglycemia is held for 1 ½ hours or 
until death. B) Mortality associated with severe hypoglycemia started as early as 25 
minutes into severe hypoglycemia with 50% mortality at 50 minutes into severe 
hypoglycemia. All rats had died 90 minutes into severe hypoglycemia. C) Heart rate 
during the clamp remains normal until just before severe hypoglycemia when glucose 
levels reach ~35 mg/dl at which time heart rate increases. At the onset of severe 
hypoglycemia, heart rate decreases. Heart increases again immediately prior to death. 
The slower heart rates that occur towards the end of the clamp can be attributed to 
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multiple cardiac arrhythmias associated with bradycardia. D) QTc prolongation starts to 
occur during insulin infusion when glucose levels are moderately hypoglycemic (~35 
mg/dl) and persists into severe hypoglycemia. Mean QTc during severe hypoglycemia 
increased to 158+5 ms compared to 122+2 ms in the basal period (p<0.01). E) 
Epinephrine levels increased from 495+60 in the basal period and peak at 3034+383 
pg/ml at the onset of severe hypoglycemia, but decline as severe hypoglycemia persists 
(p<0.001). F) Norepinephrine levels increased from 197+20 in the basal period and start 
to increase at the onset of severe hypoglycemia and continue to rise throughout severe 
hypoglycemia, peaking at 748+116 pg/ml (p<0.001). n=6; Data expressed as 
mean+sem. 
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Figure 22. ECG changes in response to severe hypoglycemia (study 3). 
Electrocardiogram (ECG) recordings from one representative control rat from basal 
(euglycemia) through severe hypoglycemia induced death. The order of the graphs is a 
typical representation of what occurs in all rats during severe hypoglycemia and just 
prior to death. At the top of the left column, the ECG shows a rat in normal sinus rhythm 
during euglycemic conditions. During moderate hypoglycemia, cardiac arrhythmias are 
rarely witnessed. At the start of severe hypoglycemia, heart rate tends to return to basal 
levels followed by QTc prolongation and the initiation of several types of cardiac 
arrhythmias. Cardiac arrhythmias that occur during severe hypoglycemia are premature 
atrial contractions (PAC noted by arrow), premature ventricular contractions (PVC noted 
by arrow), nonsustained ventricular tachycardia (v-tach), 1st degree heart block (PR 
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prolongation noted by arrow), and occasional 2nd degree heart block (absent QRS 
complex noted by arrow).  With severe hypoglycemia of increased duration, frequency 
of 2nd degree heart block increases followed by 3rd degree heart block. At the time 
cardiorespiratory arrest, heart rate is markedly decreased. 
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Figure 23. Arrhythmias, blood gas, and blood pressure in response to severe 
hypoglycemia in control experiments (study 3). A) Frequency of both PVCs and 2nd 
degree heart block occur at a rate of 1.4+0.74 and 2+0.78 per minute, respectively, 
during severe hypoglycemia. B) 3rd degree heart block occurred in 100% of the rats and 
v-tach occurred in 75% of the rats. C) Oxygen (open diamond, left axis) and carbon 
dioxide (black square, right axis) levels remain normal during severe hypoglycemia 
(97% O2 and 32 mmHg CO2). During apnea and just prior to death, oxygen levels 
decrease (38+6%) and carbon dioxide levels increase (53+3 mmHg). D) Blood pressure 
increased at the start of severe hypoglycemia and remained elevated throughout severe 
hypoglycemia. Blood pressure decreased as the rats died. n=6. Data expressed as 
mean+sem. 
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Figure 24. Electroencephalogram (EEG) recordings in response to hypoglycemia 
in a control rat during a hyperinsulinemic/severe hypoglycemia clamp (study 3). 
The progressive series of EEG recordings initially shows basal brain activity during the  
euglycemic state followed by slow, high amplitude brain waves, characteristic of severe 
hypoglycemia. Isoelectric activity on the EEG corresponded to rats in a comatose state. 
The sudden onset of chaotic, high amplitude EEG voltages of short duration (~5 
seconds) corresponded to visible tonic-clonic seizure-like behavior. 
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Figure 25. Severe hypoglycemic clamp with ICV glucose infusion (study 4). A) 
Mortality due to severe hypoglycemia was significantly reduced from 89% in ICV 
mannitol to 33% in ICV glucose infused rats (*p<0.05 Fisher exact test, Freeman-Halton 
extension). B) Blood glucose levels were evenly matched between the ICV mannitol 
(white circle) and ICV glucose (black circle) infused rats. Once blood glucose levels 
reached 15 mg/dl, severe hypoglycemia was started (time 0). Severe hypoglycemia was 
held for a duration of 3 hours. C) Mean glucose infusion rates during severe 
114 
 
hypoglycemia were significantly elevated in ICV glucose (black bar) infused rats 
(5.4+0.6 mg/kg/min) compared to ICV mannitol (white bar) infused rats (4.2+0.41 
mg/kg/min). *p<0.01 ttest. D) Heart rate remained normal compared to basal in both 
groups until 45 minutes into severe hypoglycemia when ICV mannitol infused rats had 
elevated heart rate. ICV glucose infused rats had lower heart rates throughout severe 
hypoglycemia compared to ICV mannitol infused rats. Mean heart during severe 
hypoglycemia was 414+9 BPM and 357+8 in ICV mannitol and ICV glucose infused 
rats, respectively (*p < 0.05 ttest). E) The QTc length was increased after the start of 
insulin infusion during moderate hypoglycemia and reached statistical significance at 30 
minutes into insulin infusion. During severe hypoglycemia, QTc length was not different 
between ICV mannitol and ICV glucose infused rats with mean QTc values of 180+2 
and 187+3 ms, respectively. F) Norepinephrine levels were increased during severe 
hypoglycemia in ICV mannitol infused rats compared to the basal state, but this 
response was blunted in ICV glucose infused rats. *p<0.05, ttest. n=9/group. Data 
expressed as mean+sem. 
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Figure 26. Mortality and arrhythmia incidence in ICV glucose infusion (study 4). A) 
Mortality incidence was associated with duration of sinus tachycardia (heart rates 
greater than 400 bpm). Tachycardia lasting <15 minutes resulted in no mortality. 
Tachycardia lasting 16-30 minutes resulted in 17% and 20% death in the ICV mannitol 
and ICV glucose infused rats, respectively. Tachycardia lasting longer than 30 minutes 
led to 80% death in ICV mannitol infused rats but only 50% death in ICV glucose 
infused rats. B) The incidence of mortality increased with increased duration of 
ventricular depolarization/repolarization dispersion as noted by greater QTc 
prolongation. Basal QTc duration was 122+2 ms but increased in response to 
hypoglycemia. Increased QTc lengths of 150-179 ms did not increase mortality.  
Increased QTc lengths of 180-200ms was associated with 14 and 13% mortality in ICV 
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mannitol and ICV glucose infused rats, respectively. QTc lengths of more than 200 ms 
was associated with 83% mortality in ICV mannitol infused rats but only 40% in ICV 
glucose infused rats. C) During severe hypoglycemia, the frequency of premature 
ventricular contractions (PVCs) was nonsignificantly reduced from 2.2+1.2 per minute in 
ICV mannitol to 0.54+0.32 per minute in ICV glucose infused rats (p = 0.07).  D) During 
severe hypoglycemia, the frequency of 2nd degree heart block was 2.6+0.66 and 
1.1+0.45 per minute for ICV mannitol and ICV glucose infused rats (p=NS). E) During 
severe hypoglycemia, the incidence of 3rd degree heart block was 89% and 38% for the 
ICV mannitol and ICV glucose infused rats (*p<0.05). F) Ventricular tachycardia (v-tach) 
during severe hypoglycemia occurred in 38% of the ICV mannitol infused rats but none 
of the ICV glucose infused rats experienced v-tach (p=NS). white circle/bar= ICV 
mannitol; black circle/bar= ICV glucose. *p<0.05, ttest. n=9/group. Data expressed as 
mean+sem. 
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Figure 27. Severe hypoglycemic clamp with adrenergic blockade (study 5). A) 
Control rats had a mortality rate of 33% (n=12) in response to severe hypoglycemia. 
Alpha blockade had no effect on mortality (50%; n=6). Death was prevented in both  
(n=13) and  blocker (n=5) infused rats (*p<0.029, Fisher exact test, Freeman-Halton 
extension). B) Glucose levels were evenly matched throughout the clamp. Glucose was 
clamped between 10-15 mg/dl for 3 hours. C) Mean glucose infusion rate during severe 
hypoglycemia.  blockade significantly increased glucose infusion rate. Alpha 
blockade and beta blockade alone did not differ compared to controls but  blocker rats 
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had lower glucose infusion rate compared to  blocker and  blocker infused rats 
(p<0.05, ANOVA). D) Heart rate was consistently lower in  and  blockade rats 
throughout the clamp compared to control and  blockade rats (*p<0.001 for individual 
timepoints, ANOVA). E) QTc length was significantly increased in all groups during 
severe hypoglycemia (p<0.001, ANOVA). Combined / blockade significantly blunted 
the QTc prolongation compared to controls (*p<0.001 for mean QTc during severe 
hypoglycemia, ANOVA). White circle= control; black circle= (a/b) blocker; white 
triangle=  (a) blocker; black triangle=  (b) blocker. Data expressed as mean+sem. 
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Figure 28. Insulin levels, mortality incidence and blood pressure levels during 
severe hypoglycemia with or without adrenergic blockade (study 5). A) Insulin 
levels were not different among the groups in the basal or severe hypoglycemia periods. 
B) Incidence of severe hypoglycemia induced death was increased with duration of 
sinus tachycardia (defined as >400BPM). Tachycardia did not develop in  or  
blocker rats. Alpha blockade rats all died with less than 15 minutes of tachycardia 
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whereas control rats had 100% mortality with more than 30 minutes of tachycardia. C) 
Incidence of mortality increased with QTc length. During severe hypoglycemia, rats that 
had a QTc prolongation of 150-179ms all survived, whereas in rats where hypoglycemia 
increased QTc lengths to 180-200ms there was an associated increase in mortality to 
25% in control rats. In control and alpha blockade rats, QTc prolongation of more than 
200ms resulted in 33% and 67% mortality, respectively. D and E) Systolic (D) and 
diastolic (E) blood pressure (BP) during severe hypoglycemia were lower in  blocker 
infused rats compared to controls (*p<0.001 Two-way ANOVA). White bar= control; 
black bar= (a/b) blocker; diagonal slash=  (a) blocker; horizontal slash=  (b) 
blocker. n=5-13. Data expressed as mean+sem. 
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Figure 29. Severe hypoglycemia induced arrhythmias and catecholamines levels 
during adrenergic blockade (study 5). A) As compared to control rats, PVC frequency 
during severe hypoglycemia was significantly decreased in  and  blockade rats (*p 
< 0.001, ANOVA) with a trend for decreased frequency in  blockade rats. B) Second 
degree heart block frequency was significantly reduced in  blockade rats with only 1 
rat experiencing 2nd degree heart block. Alpha and beta blockade alone trended to 
reduce frequency of 2nd degree heart block but this was not significantly different 
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compared to controls. C) Incidence of 3rd degree heart block was 40% in control rats 
and 16% in  blockade rats. No 3rd degree heart block occurred in  or  blockade 
rats. (*p<0.02 Fisher exact test, Freeman-Halton extension). D) Epinephrine levels 
increased significantly in all groups during severe hypoglycemia. The beta blockade 
group had significantly higher epinephrine levels compared to all other groups. (*p<0.01 
ANOVA) E) Norepinephrine levels increased significantly in all groups during severe 
hypoglycemia. Norepinephrine levels in the alpha blockade group were significantly 
higher compared to all 3 other groups. (*p<0.001 ANOVA). White bar= control; black 
bar= (a/b) blocker; diagonal slash=  (a) blocker; horizontal slash=  (b) blocker. 
n=5-13. Data expressed as mean+sem. 
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Basal 
Severe 
Hypoglycemia Pre-death 
Epinephrine 
(pg/ml) 
495 
+60 
2561a 
+345 
n/a 
Norepinephrine 
(pg/ml) 
197 
+20 
743a 
+103 
n/a 
Oxygen (SO2%) 98 
+0.2 
97 
+1.5 
38a 
+5.7 
Carbon Dioxide 
(mmHg) 
31 
+1.3 
31 
+0.79 
53a 
+2.8 
Potassium 
(mmol/l) 
4.16 
+0.15 
2.96a 
+0.06 
4.46 
+0.36 
pH 7.45 
+0.01 
7.44 
+0.01 
7.22a 
+0.03 
Calcium (mmol/l) 0.89 
+0.07 
0.96 
+0.08 
0.9 
+0.09 
Bicarbonate 
(mmol/l) 
21.7 
+0.97 
21.9 
+0.49 
20.5 
+0.78 
 
Table 1. Hormones and arterial blood gas and electrolytes in control experiments 
(study 3). Epinephrine and norepinephrine increased during severe hypoglycemia. 
Oxygen and carbon dioxide levels remain normal during severe hypoglycemia 
compared to basal. Just prior to death, oxygen levels decrease and carbon dioxide 
levels increase. Potassium levels slowly decline during insulin infusion with significantly 
lower potassium levels during severe hypoglycemia. Just before death, potassium 
levels increase. pH levels remain normal throughout severe hypoglycemia but just prior 
to death. Calcium and bicarbonate levels were not significantly different throughout the 
clamp. ap<0.05 vs basal. n=6. Data represented as mean+sem. 
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Basal 
Severe 
Hypoglycemia Pre-death 
 MAN GLU MAN GLU MAN GLU 
Glucose  
(mg/dl) 
86 
+3 
86 
+4 
12a 
+0.09 
12a 
+0.16 
N/A N/A 
Insulin  
(pg/ml) 
166 
+14 
128 
+51 
7482a 
+776 
8828a 
+492 
N/A N/A 
Epinephrine 
(pg/ml) 
79 
+30 
67  
+12 
1926a 
+320 
2155a  
+448 
1453a 
+872 
1677a 
+1306 
Norepinephrine 
(pg/ml) 
181 
+27 
181 
+17 
1441a 
+646 
464ab 
+48 
2371a 
+1785 
3010a 
+1697 
Potassium 
(mmol/l) 
4.66 
+0.13 
4.43 
+0.13 
3.58a 
+0.14 
3.14ab 
+0.17 
4.25 
+0.3 
3.95 
+0.24 
Oxygen 
(SO2%) 
97 
+0.23 
97 
+0.29 
96 
+1.8 
98 
+0.13 
35a 
+10 
18a 
+0.18 
Carbon Dioxide 
(mmHg) 
29 
+0.49 
31 
+0.65 
27 
+1.3 
31 
+1.24 
47a 
+3.3 
53a 
+5.1 
Respiration 
(breaths/min) 
94 
+3 
95 
+4 
85 
+4 
78a 
+4 
30a 
+9 
54a 
+28 
 
Table 2. Glucose, hormones, and arterial blood gas and electrolytes for ICV 
glucose study (study 4). Blood glucose levels were evenly matched during severe 
hypoglycemia in both ICV mannitol (MAN) and ICV glucose (GLU) groups. Insulin 
increased to a similar extent in the severe hypoglycemic clamp in both groups. 
Epinephrine and norepinephrine increased during severe hypoglycemia to the same 
extent in both groups. Just prior to death, norepinephrine increased in both treatment 
groups. Potassium decreased to a similar extent in both groups during severe 
hypoglycemia. Blood oxygen and carbon dioxide remained normal during severe 
hypoglycemia compared to the basal state. Blood oxygen levels decreased, and carbon 
dioxide levels increased, in rats that died in both groups immediatel prior to death,. 
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Respiration remained normal in control rats during severe hypoglycemia but ICV 
glucose infused rats had lower respiration compared to the basal state. Prior to death, 
respiration significantly decreased in both groups. ap<0.05 vs basal, bp<0.05 vs control, 
ttest. n=9/group. Data represented as mean+sem. 
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  CON  blockers  blocker  blocker 
Glucagon 
(AUC) 
 
3733 
+1342 
4137 
+751 
10096b 
+1192 
4559 
+483 
Potassium 
(mmol/l) 
 
 
Basal 
 
4.4 
+0.14 
4.0 
+0.11 
4.7 
+0.09 
5.0 
+0.14 
Severe 
Hypoglycemia 
3.12a 
+0.18 
2.84a 
+0.08 
3.01a 
+0.21 
3.74ab 
+0.05 
Pre-Death 
3.6 
+0.48 
N/A 4.2 
+0.21 
N/A 
Oxygen 
(SO2%) 
 
Basal 
 
96 
+1.9 
97 
+0.28 
97 
+0.3 
97 
+0.32 
Severe 
Hypoglycemia 
97 
+0.34 
98 
+0.15 
98 
+0.36 
98 
+0.14 
Pre-Death 
26a 
+12 
N/A 
 
35a 
+0.28 
N/A 
Carbon Dioxide 
(mmHg) 
 
Basal 
 
32 
+1.7 
33 
+0.69 
32 
+0.87 
34 
+0.91 
Severe 
Hypoglycemia 
32 
+1.4 
38ab 
+0.97 
36 
+2.2 
42ab 
+2.2 
Pre-Death 
48a 
+2.5 
N/A 63a 
+11 
N/A 
Respiration 
(breaths/min) 
Basal 
 
86 
+4 
88 
+4 
96 
+8 
86 
+4 
Severe 
Hypoglycemia 
76 
+3 
51ab 
+2 
66a 
+8 
54ab 
+2 
Pre-Death 
28a 
+8 
N/A 8 N/A 
Table 3. Glucagon, arterial blood gas and electrolytes for adrenergic blockade 
study (study 5). Glucagon area under the curve (AUC) was greater in alpha blockade 
rats and similar between combined alpha/beta and beta blockade rats compared to 
controls. Potassium levels decreased in all groups during severe hypoglycemia. Beta 
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blockade resulted in higher potassium levels during severe hypoglycemia compared to 
controls. Oxygen saturation remained normal in all groups throughout severe 
hypoglycemia. Prior to death in control and alpha blocker infused rats, oxygen 
decreased compared to basal. Carbon dioxide was higher during severe hypoglycemia 
in , , and  blocker infused rats compared to basal and control. Just prior to death 
in control and blockade rats, carbon dioxide levels increased. Respiration was 
significantly decreased during severe hypoglycemia in , , and  blocker infused rats 
compared to basal. Respiration was lower during severe hypoglycemia in  and  
blocker infused rats compared to controls. Respiration decreased just prior to death in 
control  blocker infused rats. ap<0.05 vs basal, bp<0.05 vs control. n=5-13; Data 
represented as mean+sem.  
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Discussion 
Mortality due to iatrogenic insulin administration represents a major concern for 
insulin treated diabetic patients and their families. Determining the mechanisms by 
which hypoglycemia induces sudden death is critically important in order to find 
treatments to protect patients who are at risk.  Animal studies are needed to investigate 
the causes of mortality associated with severe hypoglycemia. In the current study, 
diabetes was found to exacerbate, while recurrent hypoglycemia was found to 
attenuate, severe hypoglycemia-induced sudden death. The cause of death in these 
preliminary rat studies was unknown. Cardiac arrhythmias have been shown to occur 
during moderate hypoglycemia in humans88 and fatal cardiac arrhythmias are 
speculated to mediate the “dead in bed syndrome” but no studies to date have shown 
this as it is difficult to investigate in the clinical setting. Using a rat model, we show for 
the first time that fatal cardiac arrhythmias occur as a result of severe hypoglycemia and 
such arrhythmias can be reduced by ICV glucose infusion and prevented by beta 
adrenergic blockade. These results indicate that brain neuroglycopenia and the 
sympathoadrenal response mediate fatal cardiac arrhythmias that occur during severe 
hypoglycemia (figure 30).  
Diabetes increased mortality due to severe hypoglycemia although the 
mechanism(s) involved remains unclear. Uncontrolled diabetes is hypothesized to 
increase risk of fatal cardiac arrhythmias. Diabetes has been shown in animal models to 
alter the myocardium composition152 and lead to cardiac mechanical defects such as 
defects in left ventricular function and velocity ejection153. Aside from chronic 
maladaptations associated with insulin deficiency, it may be that the greater absolute 
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decrement in blood glucose in diabetic (eg, from 348 to 12 mg/dl) versus control rats 
(from 88 to 12 mg/dl) may have contributed to overall increased mortality by inducing a 
greater net insult going from high to low glucose levels. Although STZ diabetic rats have 
been shown to be at higher risk for arrhythmias154, in the absence of ECG data from 
these preliminary experiments, the cause of increased mortality rates in diabetic rats 
remains unknown.  
Recurrent hypoglycemia significantly reduced severe hypoglycemia-induced 
mortality. These findings are consistent with a pre-conditioning effect of recurrent 
hypoglycemia to limit severe hypoglycemia induced seizures, brain damage and 
cognitive dysfunction60.  It is speculated that the blunted catecholamine response that 
occurred with recurrent hypoglycemia may be the mechanism by which recurrently 
hypoglycemic rats were protected from death.  Interestingly, the blunted catecholamine 
response in the recurrently hypoglycemic rats apparently rendered them more prone to, 
but paradoxically less vulnerable to, an otherwise lethal episode of severe 
hypoglycemia. This putative mechanism is supported by the beta blockade treatment 
study that noted reduction of arrhythmias and prevention of death. In the absence of 
ECG recordings though, the extent to which cardiac arrhythmias were reduced by 
antecedent recurrent hypoglycemia is unknown. 
As compared to human ECG recordings, rat ECGs are characterized by shorter 
interval durations, more rapid heart rate, absent Q waves, and absence of an isoelectric 
ST segment155. Supporting our assertion that the reported ECG changes truly reflect 
ECG responses in humans, similar to the presented rate and rhythm disturbances noted 
by ECG monitoring in the current rat study, clinical ECG observations during 
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hypoglycemia include QTc prolongation87-89,156, sinus bradycardia85,156, and  multifocal 
ventricular ectopies85. Furthermore, rats respond to the effects of anti-arrhythmic agents 
such as adrenoreceptor blockers similar to humans as seen previously in a rat model in 
which combined alpha and beta adrenergic receptor blockade reduced sinus 
tachycardia and ST elevation induced by immobilization stress98. Taken together, the rat 
ECG changes presented in these studies closely resemble those observed in humans 
during hypoglycemia, indicating that beta blockers have clinical significance to prevent 
severe hypoglycemia-induced cardiac arrhythmias and sudden death.  
The mechanisms regulating severe hypoglycemia-induced sudden death are 
thought to be multifactorial; however, in these experiments a timeline of events leading 
to sudden death (Figure 31) can be summarized as follows: 1) In the setting of 
hyperinsulinemia, mild hypokalemia and mild QTc prolongation manifest first, even 
during euglycemic conditions. 2) As glucose levels are further lowered, potassium levels 
continue to drop even further and QTc prolongation increases reaching its maximum 
during severe hypoglycemia. Rarely, minor cardiac arrhythmias, such as PACs, are 
witnessed during more moderate levels of hypoglycemia (20-40 mg/dl) but were never 
witnessed during euglycemic conditions. 3) At the onset of severe hypoglycemia, 
epinephrine levels peak. 4) Cardiac arrhythmias develop shortly after, including PVCs, 
1st and 2nd degree heart block, ventricular tachycardia, and atrial fibrillation. 5) 
Norepinephrine levels peak near 1 hour of severe hypoglycemia. 6) Shortly thereafter, 
sinus tachycardia occurs, and if not spontaneously corrected is very predictive of 
ensuing death. 7) In rats that die, sinus tachycardia is followed by increased frequency 
of PVCs and high grade 2nd degree heart block. 8) If sinus tachycardia is not 
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spontaneously reversed, 3rd degree heart block is most often seen as the terminal 
cardiac rhythm that is associated with profound bradycardia followed by the rapid 
sequential onset of reduced cardiac output (noted by hypotension), respiratory 
depression, hypoxemia, hypercarbia, and acidosis. Sinus tachycardia and 3rd degree 
heart block were the strongest predictors of sudden death due to hypoglycemia. The 
sensitivity and specificity of sinus tachycardia (hear rate > 400 bpm) as a predictor of 
mortality was 88% and 74%, respectively, while 3rd degree heart block was 89% and 
95%, respectively. Other predictors of mortality in the current experiments were QTc 
prolongation and increased frequency of 2nd degree heart block. The sensitivity and 
specificity of QTc prolongation (>200ms) as a predictor of mortality was 81% and 60%, 
respectively, while the sensitivity and specificity of 2nd degree heart block was 94% and 
53%, respectively.   
Moderate hypoglycemia has been previously shown to lead to QTc prolongation, 
which is known to be proarrhythmic85-89. In the present studies, severe hypoglycemia 
induced a significant increase in QTc length indicating that hypoglycemia induces a type 
of acquired long-QTc syndrome. QTc lengthening was associated with increased risk of 
mortality. With adrenergic blockade, blunting the rise in QTc during hypoglycemia may 
have contributed to the reduced incidence of arrhythmias and ultimately the prevention 
of death. However, hypoglycemia induced QTc prolongation in beta blocker and ICV 
glucose infused rats were similar to their respective controls indicating that QTc 
prolongation per se does not lead to cardiac arrhythmias and death. Since providing the 
brain with glucose reduced mortality but did not reduce QTc prolongation, it is 
concluded that systemic factors such as low glucose, low potassium, and elevated 
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epinephrine levels that affect ventricular dispersion, and not neuroglycoenia per se, that 
regulate QT length. Taken together, these studies indicate that QTc prolongation is a 
marker of severe hypoglycemia and is predictive of ensuing cardiac arrhythmias, but is 
not sufficient to cause cardiac arrhythmias.  
A role for potassium in regulation of cardiac arrhythmias has been noted88,97. 
Hypokalemia can trigger cardiac arrhythmias during moderate hypoglycemia in 
humans88. In addition, potassium supplementation in the current studies trended to 
reduce mortality in non-diabetic and diabetic rats indicating that hypokalemia increases 
risk of death due to severe hypoglycemia. However, because the mortality differences 
were not significant, it is still undetermined to what extent hypokalemia regulates severe 
hypoglycemia induced sudden death. 
Blood potassium levels are known to be regulated by insulin, adrenergic 
activation and pH, each of which affects potassium entry into cells157. 1) Insulin is 
known to lower plasma potassium levels by increasing potassium entry into cells. Insulin 
was shown to lower blood potassium levels during euglycemic conditions during the 
clamps but hypokalemia did not cause cardiac arrhythmias in this euglycemic setting 
indicating that low glucose levels are required in addition to hypokalemia to cause 
arrhythmias. 2) Beta and alpha adrenergic receptor stimulation are known to increase 
and decrease potassium entry into the cell thus resulting in decreased and increased 
potassium in the blood, respectively. In the current studies, beta blockade led to 
significantly higher blood potassium levels whereas alpha blockade led to a 
nonsignificant decrease in potassium levels during the clamp. Interestingly, combined 
alpha/beta blockade led to similar blood potassium levels as controls. This indicates that 
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although potassium levels were higher in the beta blockade group, this is not 
necessarily why mortality was prevented in this group because combined alpha/beta 
blockade resulted in potassium levels similar to controls yet all rats in this group lived. 3) 
Finally, acidosis is known to impair potassium entry into the cell thus leading to elevated 
plasma potassium. pH levels did not change during the clamps until just before death 
when acidosis occurred. When acidosis occurred it was also noted that hyperkalemia 
was present. However, hyperkalemia is not considered a cause of death but rather a 
result of acidosis. Taken together, the results from these studies indicate that the level 
of hypokalemia achieved in the setting of insulin induced hypoglycemia was not 
sufficient, or not of sufficient magnitude, to cause lethal cardiac arrhythmias.  
Cardiac arrhythmias can also result from changes in respiration. In the current 
studies, the respiratory rate decreased slightly as the rats entered a severe 
hypoglycemia-induced coma, but the respiratory rate declined to a similar extent in all 
groups, although sometimes lower with beta blockade. Since there was no difference in 
the respiratory rate and since oxygen and carbon dioxide levels did not change during 
the clamps, it can be concluded that respiratory arrest developed only after cardiac 
arrest. Therefore, defects in respiration or respiratory drive, including brief post-ictal 
apneic episodes, are not primary contributors to severe hypoglycemia-induced sudden 
death but rather occur following a terminal cardiac arrhythmia.  
Another potential contributor to cardiac arrhythmias is marked changes in blood 
pressure. During severe hypoglycemia, decreased cardiac output and resultant 
hypotension could lead to decreased blood flow to the brain and/or heart thereby 
increasing risk for fatal cardiac arrhythmias. However, based on the current studies, 
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blood pressure was maintained throughout the period of severe hypoglycemia and was 
therefore not thought to contribute to severe hypoglycemia induced mortality. In the 
control experiments from study 3, blood pressure was elevated during severe 
hypoglycemia and only dropped following a terminal bradycardic arrhythmia. It is 
surmised that hypotension did not contribute to cardiac death, but rather was a marker 
of sudden cardiac failure.  
In addition to the above mentioned peripheral effects of insulin-induced severe 
hypoglycemia, central effects on hypoglycemic counterregulation are also important. In 
particular, the hypothalamus plays a critical role in regulating the hypoglycemic 
counterregulatory response. Low glucose in the ventromedial hypothalamus (VMH) is 
required for local release of norepinephrine15 which leads to increased adrenergic 
signaling and epinephrine release from the adrenal gland. Since glucose infusion into 
the VMH blunts the counterregulatory response to hypoglycemia in a dose dependent 
manner158 and brain centers are known to control heart contractility and respiration159, it 
was hypothesized that if the brain has an adequate glucose supply during a 
hyperinsulinemic/severe hypoglycemic clamp, then cardiac arrhythmias and mortality 
would be reduced. Consistent with previous studies using a low dose of ICV glucose 
infusion158, the ICV glucose dose infused in the current study was not enough to blunt 
the epinephrine response; however, the norepinephrine response was blunted. 
Interestingly, the blunted norepinephrine response during ICV glucose infusion may 
have contributed to reduced mortality. Although epinephrine remained elevated, heart 
rate in the ICV glucose infused rats was normal possibly due to the blunted 
norepinephrine response and/or an increased vagal tone. Reduced mortality rate with 
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ICV glucose infusion reveals that the brain plays an important role in maintaining normal 
heart rate and reducing cardiac arrhythmias during severe hypoglycemia even in the 
presence of elevated epinephrine. It can be concluded from the current studies that 
brain neuroglycopenia contributes to severe hypoglycemia-induced cardiac arrhythmias 
and mortality. Further research should focus on how cellular changes in brain glucose 
sensing and efferent pathways that occur during severe hypoglycemia may contribute to 
sudden death.  
Hypoglycemic seizures were also noted to occur in most rats. However, with the 
exception of the recurrent hypoglycemia protocol, even though the incidence of seizures 
tended to be reduced in some studies, there was no correlation found between number 
of visible seizure-like activity and survival benefit. Consistent with other studies 
demonstrating survival following hypoglycemia induced seizures60,61 these current 
studies indicate that seizures are not a primary contributor to severe hypoglycemia-
induced mortality but rather serve as a marker of severe hypoglycemia.  
Whether central or systemic, the rise in catecholamines during severe 
hypoglycemia was hypothesized to increase risk of cardiac arrhythmias and sudden 
death. By blocking the effects of catecholamines (epinephrine and norepinephrine) with 
simultaneous / or single  adrenergic receptor blockers during a hyperinsulinemic, 
severe hypoglycemic clamp, glucose infusion rate increased, heart rate decreased, and 
cardiac arrhythmias were reduced. The major finding of these studies is that combined 
alpha/beta and single beta adrenergic blockade prevented death. These studies 
indicate that enhanced catecholamine signaling through beta adrenergic receptors 
mediates fatal cardiac arrhythmias in the setting of severe hypoglycemia. 
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Beta blockade (propranolol) is known to reduce the clearance of epinephrine and 
norepinephrine. This correlates with the observed increased epinephrine in the beta 
blockade group and the trend for an increased norepinephrine160. Similarly, alpha 
blockade (phentolamine) has been shown previously to double plasma norepinephrine 
levels160, which in the present study norepinephrine was increased 2.8 fold with 
prazosin.  
Although adrenergic receptors located within the brain have been shown to be 
involved in mediating the counterregulatory response36, the current study cannot 
distinguish whether the adrenergic blocker effect was mediated via central or peripheral 
actions. However, regardless of their site of action, their effect was profound. It is 
speculated that the beta-adrenergic norepinephrine response, may be the lethal 
arrhythmogenic provocateur, based on the following observations:  1) epinephrine levels 
peaked early, at the onset of severe hypoglycemia, then declined before the onset of 
serious arrhythmias; whereas norepinephrine levels continued to rise during severe 
hypoglycemia and peaked immediately before the time of arrhythmogenic death, 2) the 
reduced rates of hypoglycemia-induced arrhythmias and deaths with ICV glucose 
infusion was associated with a blunted norepinephrine response and not a blunted 
epinephrine response, and 3) beta, not alpha adrenergic blockade, markedly reduced 
arrhythmias and completely prevented death, even in the presence of high epinephrine 
levels. Taken together, it is proposed that it was the hypoglycemia-induced increased 
norepinephrine response, acting primarily via beta adrenergic receptors, that mediated 
the severe hypoglycemia-induced fatal cardiac arrhythmias. 
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Cardiac specific beta blockers (ie, β1 blockers), that do not adversely limit the 
counterregulatory response to hypoglycemia, have been shown to prevent QTc 
prolongation associated with moderate hypoglycemia88. In the current study, non-
selective beta-blockade did not prevent QTc prolongation, but more importantly, 
reduced the incidence of life-threatening arrhythmias and overall mortality associated 
with severe hypoglycemia. Future research is needed to investigate potential life-saving 
effects of adrenergic 1 and/or 2 receptor blockade in the setting of hypoglycemia.   
 
Summary 
Under the conditions studied, diabetes worsens, while recurrent antecedent 
hypoglycemia protects against severe hypoglycemia-induced mortality. Thus, the odds 
of surviving an episode of severe hypoglycemia are dependent on antecedent blood 
sugar control. Seizures are markers of severe hypoglycemia, but are not sufficient to 
cause death. Under the conditions studied, severe hypoglycemia-induced sudden death 
is caused by fatal cardiac arrhythmias. Deaths due to severe hypoglycemia were 
mediated by brain neuroglycopenia and the counterregulatory sympathoadrenal 
(adrenergic) response that lead to fatal cardiac arrhythmias (3rd degree heart block with 
a slow ventricular response) causing low cardiac output (hypotension) followed by 
respiratory arrest. Implications of the current studies could lead to improvement in 
treatment strategies that aim to reduce mortality of individuals at high risk for insulin-
induced hypoglycemia.  
  
138 
 
 
Figure 30. Proposed mechanism of sudden cardiac death due to insulin-induced 
severe hypoglycemia. Hypoglycemia is detected at the level of the brain. Through 
autonomic innervation, local release of norepinephrine at nerve terminals within the 
heart may lead to fatal cardiac arrhythmias. Autonomic innervation of the adrenal gland 
results in epinephrine release. Both circulating epinephrine in addition to circulating 
norepinephrine act at the level of the heart to increase risk of fatal cardiac arrhythmias. 
Within the blood, hypokalemia is also thought to contribute to hypoglycemia induced 
cardiac arrhythmias. Both these direct and indirect actions on the heart lead to QTc 
prolongation, but QTc prolongation is not thought to be a major contributor to mortality. 
Hypoglycemia induced sudden cardiac death results from enhanced adrenergic 
signaling at the level of the heart that leads to sinus tachycardia. Tachycardia is 
followed by 3rd degree heart block that culminates into a fatal bradycardic rhythm 
causing cardiorespiratory failure and sudden death. Red= circulating glucose, 
electrolytes, and hormones; blue= autonomic innervation 
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Figure 31. Timeline of events leading to severe hypoglycemic sudden death. 
During hyperinsulinemic/euglycemic conditions when glucose is ~79 mg/dl, hypokalemia 
occurs and QTc prolongation begins. During moderate levels of hypoglycemia (~40 
mg/dl), PACs occur occasionally. At the start of severe hypoglycemia (15 mg/dl), 
epinephrine peaks. As severe hypoglycemia prolongs, hypokalemia worsens, QTc 
prolongation peaks, and cardiac arrhythmias develop (PVCs and 1st and 2nd degree 
heart block). Norepinephrine peaks around 1 hour into severe hypoglycemia and is 
followed by tachycardia. If tachycardia is followed by a return to normal sinus rhythm, 
the rat survives. If tachycardia is followed by an increase in the frequency of PVCs and 
2nd degree heart block, then 3rd degree heart block associated with bradycardia will 
manifest and lead to sudden cardiac death. PAC= premature atrial contraction, PVC= 
premature ventricular contraction   
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Chapter 5: Thesis Discussion 
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Regulation of glucose homeostasis involves coordination between liver, muscle, 
adipose tissue, and brain. The major understanding of the pathogenesis of insulin 
resistance characterized by Type 2 diabetes stems from research on skeletal muscle 
and adipose tissue in which a reduced ability to translocate GLUT4 to the plasma 
membrane in these tissues characterizes glucose intolerance and insulin resistance1,2. 
In recent years, the role of the brain in regulating overall energy homeostasis has been 
emphasized. In particular, the hypothalamus consists of integrated neural networks with 
both efferent and afferent pathways leading to and from the periphery, respectively, to 
control whole body glucose homeostasis. Therefore, studying the role of brain glucose 
sensing in the settings of both euglycemic and hypoglycemic conditions is important to 
understanding the etiology of normal glucose homeostasis and altered glucose 
homeostasis as occurs in conditions such as insulin resistance in diabetes.  
 
Glucose transporter 4 
 GLUT4 is an insulin responsive glucose transporter that is required in muscle 
and/or adipose for normal glucose homeostasis. To emphasize the important role for 
GLUT4 in mediating glucose homeostasis, GLUT4 knockout in skeletal muscle and 
adipose tissue leads to glucose intolerance and insulin resistance, hallmarks of Type 2 
diabetes1,2. GLUT4 is also present in the brain with differential regional expression in 
hypothalamus, hippocampus, cortex, cerebellum, and other regions21. Since the 
hypothalamus is an important neural center that mediates many metabolic regulatory 
pathways, understanding GLUT4 action in this region is integral to understanding 
normal glucose homeostasis.  
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Insulin action in the brain is known to control hepatic glucose production and the 
counterregulatory response to hypoglycemia27,106,124. Many glucose sensing neurons 
located within the hypothalamus contain both insulin receptor and GLUT416. In addition, 
neuronal insulin receptor knockout (NIRKO) mice which exhibit impaired suppression of 
hepatic glucose production and impaired hypoglycemic regulation also have reduced 
hypothalamic GLUT4 protein expression27,106 indicating that decreased brain GLUT4 
may be contributing to the observed phenotype of NIRKO mice. However, brain 
GLUT4’s role in glucose homeostasis has not been clearly defined. As an insulin 
sensitive glucose transporter, a role in glucose uptake in the brain would need to be one 
of metabolic importance to be initiated only when insulin is present. Studies presented 
in this thesis have revealed the importance of brain GLUT4 in mediating whole body 
glucose homeostasis. Brain GLUT4 knockout mice exhibit glucose intolerance, hepatic 
insulin resistance, regional specific reduced brain glucose uptake, impaired 
hypoglycemic counterregulation, and impaired glucose sensing in VMH glucose 
inhibited neurons. These novel findings will help guide therapeutic strategies aimed at 
treating and preventing glucose intolerance and insulin resistance. Future research will 
need to focus on understanding how differential regional expression of the various 
glucose transporters regulate glucose metabolism and the counterregulatory response 
to hypoglycemia.   
 
Hypoglycemia 
One of the major limitations in the treatment of diabetes is hypoglycemia. Well 
controlled diabetes is essential for patients to prevent micro- and macrovascular 
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complications associated with hyperglycemia; but avoidance of hypoglycemia can be 
difficult. Severe hypoglycemia is clinically defined as a low blood sugar level during 
which time the patient is unable, by themselves, to correct their low blood sugar (ie, 
consume carbohydrates) and therefore require external assistance (from a family 
member/friend or emergency services) in order to return glucose levels to normal. In the 
lab, we define severe hypoglycemia as a glucose level of 10-15 mg/dl in order to 
maintain consistency in all studies. Clinical case reports have indicated that severe 
hypoglycemia can lead to brain damage, seizures, coma, and death, all of which are 
observed in our rat model of insulin-induced severe hypoglycemia.  
Brain damage due to hypoglycemia is disconcerting. Understanding how brain 
damage is caused is essential in order to prevent hypoglycemia mediated brain damage 
from occurring in diabetic patients at risk. In this thesis it was demonstrated that brain 
damage can be affected by antecedent glucose control. Uncontrolled diabetes 
exacerbates while insulin treated diabetes, that nearly normalizes blood glucose levels, 
reduces severe hypoglycemia induced brain damage. Interestingly, no effects on 
cognitive function were observed in this study. This indicates that although the duration 
of hypoglycemia was enough to cause some brain damage, the extent of brain damage 
was not of sufficient magnitude to translate into demonstrable cognitive deficits.  
In addition to the brain damaging effects of severe hypoglycemia, perhaps an 
even scarier reality is that severe hypoglycemia can be lethal. The ‘dead in bed’ 
syndrome refers to instances where otherwise healthy young individuals with Type 1 
diabetes are found dead in their beds in the morning with no clear cause of death upon 
autopsy69. Severe hypoglycemia has often been hypothesized to be the cause of death 
144 
 
in this syndrome. A recent case report where a patient was found dead in their bed and 
had been wearing a continuous glucose monitor revealed that severe hypoglycemia 
occurred overnight just prior to death80. This was the first case report demonstrating 
severe hypoglycemia associated with the dead in bed syndrome. However, how exactly 
severe hypoglycemia leads to sudden death in humans is unknown. Ethical limitations 
restrict the study of severe hypoglycemia in the human population. It has been 
hypothesized that fatal cardiac arrhythmias result from severe hypoglycemia but to this 
end has never been shown in clinical practice. 
In this current thesis, it is shown for the first time in a rat model that severe 
hypoglycemia leads to cardiac arrhythmias which lead to respiratory arrest. These fatal 
cardiac arrhythmias can be reduced by providing the brain with glucose thus indicating 
that neuroglycopenia plays an important role in mediating cardiac arrhythmogenic 
deaths. Similarly, fatal cardiac arrhythmias were prevented by blocking beta 
adrenorecptors indicating that the marked rise in epinephrine and norepinephrine likely 
mediate cardiac arrhythmogenic deaths.  These findings have direct clinical implications 
in that, paradoxically, blocking the actions of the catecholamines during severe 
hypoglycemia actually prevents death. These findings are consistent with the recurrent 
antecedent hypoglycemia observations. Rats exposed to recurrent moderate 
hypoglycemia for 3 days followed by a hyperinsulinemic/severe hypoglycemic (10-15 
mg/dl) clamp for 1 hour the following day had blunted sympathoadrenal responses 
which was also associated with reduced mortality due to severe hypoglycemia. Thus, 
consistent with the adrenoreceptor blockade study, blunted epinephrine response of 
rats exposed to recurrent hypoglycemia was found to significantly improve overall 
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survival.  Interestingly, in human studies, beta blockade prevented the QTc prolongation 
that normally occurs during moderate hypoglycemia88. Similarly in this thesis, beta-
adrenergic receptor blockade during severe hypoglycemia prevented both cardiac 
arrhythmias and death. Beta blockers are already in use in heart failure patients and 
improve their survival rates161. Taken together, fatal cardiac arrhythmias that occur in 
the setting of severe hypoglycemia can be prevented with beta adrenergic blockade, 
and future research should consider the use of beta blockade as a potential treatment in 
diabetic patients at risk for severe hypoglycemic cardiac arrest.  
 In addition to the catecholamine surge, hypokalemia is known to be 
proarrhythmic. Therefore, one of the goals to prevent severe hypoglycemia-induced 
mortality in our rat model was to supplement potassium during the 
hyperinsulinemic/severe hypoglycemic clamp. Severe hypoglycemia-induced mortality 
trended to be reduced in both non-diabetic and diabetic rats that received potassium 
supplementation but neither reached significance. Hypokalemia results from the 
activation of sodium/potassium ATPases by insulin and, in the subsequent ECG 
studies, hypokalemia occurred even prior to severe hypoglycemia. However, 
hypokalemia is present at equal levels in several of the studies reported in this thesis, 
including the beta blocker studies, indicating that hypokalemia itself is not sufficient to 
cause sudden death during severe hypoglycemia. However, it remains undetermined 
whether or not potassium infusion during episodes of hypoglycemia will prevent cardiac 
arrhythmias.  
 A major question remains that if we can prevent sudden death due to severe 
hypoglycemia, what will be the consequences of surviving such a severe episode? 
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Brain damage and cognitive defects as a result of severe hypoglycemia can 
tremendously decrease quality of life. Therefore, future studies need to be aimed at 
reducing severe hypoglycemia-induced brain damage and mortality simultaneously in 
order to increase quality of life in patients at risk for the damaging effects of severe 
hypoglycemia.  
 
Summary 
 Understanding the pathogenesis of diabetes is crucial in order to reduce the rise 
in diabetes prevalence. The complications of diabetes and diabetes treatments are also 
important to study due to the very high incidence of diabetes in the world. The 
mechanisms of the etiology of glucose intolerance and insulin resistance are well 
defined in the periphery. However, the brain has an important role in glucose 
homeostasis and has recently gained much attention. In addition, complications of 
diabetes treatment remain a major concern for diabetic patients and their families. This 
thesis reveals how brain centers control glucose tolerance and insulin sensitivity, and 
how brain damage and mortality due to severe hypoglycemia can be prevented. First, it 
was shown that brain GLUT4 is important in regulating hepatic glucose production and 
the counterregulatory response to hypoglycemia in that knockout of brain GLUT4 led to 
glucose intolerance, hepatic insulin resistance, and impaired hypoglycemic glucose 
sensing. Second, antecedent blood glucose control regulates the extent of brain 
damage induced by severe hypoglycemia in that insulin treatment that nearly 
normalized blood glucose levels in diabetic rats reduced severe hypoglycemia-induced 
brain damage compared to uncontrolled diabetic rats. Third, severe hypoglycemia 
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induced mortality is mediated by fatal cardiac arrhythmias that can be reduced by brain 
glucose infusion and prevented by beta adrenergic blockade indicating that brain 
neuroglycopenia and enhanced catecholamine signaling are major contributing factors 
to severe hypoglycemia-induced mortality.  
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